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 Many congestive heart failure (CHF) patients may not be able to attain a peak 
respiratory exchange ratio (RERpeak) >1.10 during maximal cardiopulmonary exercise 
(CPX) testing. Although this is usually attributed to a submaximal effort, a portion of this 
population may not be able to attain this RERpeak level due to pathophysiological 
complications of heart failure. Currently, little is known about the predictive value of 
CPX testing in CHF patients with a RERpeak <1.10. Hence, the purpose of this study was 
to identify significant predictors of CHF-related adverse events in patients with a low 
RERpeak. The variables analyzed for predicting two-year survival of CHF-related events 
included V
.
E/V
.
CO2 slope, left ventricular ejection fraction (LVEF), etiology of CHF, 
beta-blocker usage, age, sex and body mass index (BMI). No use of beta-blockers,  
V
.
E/V
.
CO2 slope >34, LVEF <25%, and ischemic etiology of CHF were associated with 
significantly lower two-year CHF-related event-free survival probability within the  
V
.
O2peak <14 ml/kg/min stratum. This probability was comparable to the high RERpeak 
(>1.10) group within the same V
.
O2peak stratum. Exploratory multivariate proportional 
hazard analysis in this particular group revealed that no use of beta-blockers, V
.
E/V
.
CO2 
slope >45, LVEF <25% and ischemic etiology of CHF were the significant independent 
predictors of CHF-related events.  
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CHAPTER I 
INTRODUCTION 
 
 
This section will define the statement of the problem, purpose of the study, specific aims, 
and hypotheses.  
 
Statement of the Problem 
 Cardiopulmonary exercise (CPX) testing is the gold standard for assessing 
functional capacity and predicting prognosis in ambulatory patients with congestive heart 
failure (CHF). As a result, many heart failure specialists use CPX testing to help tailor 
therapy for individual patients based on CPX test results. In particular, CPX testing plays 
a crucial role in making referral decisions for CHF patients regarding advanced therapies 
such as heart transplantation and implantation of left ventricular assist devices (LVADs). 
Given the scarcity of donor organs and the costs associated with treating advanced heart 
failure, the ability to accurately identify patients who are at the highest risk for adverse 
outcomes is imperative. 
 Currently, peak exercise oxygen consumption (V
.
O2peak) is the most commonly 
used CPX testing parameter for assessing the prognosis of CHF patients. Typically, a
 2 
V
.
O2peak <14 ml/kg/min is the cut point where patients are considered for heart 
transplantation (Mancini et al., 1991; Roul et al., 1994). Another CPX testing variable, 
the slope of the minute ventilation (V
.
E) to CO2 production (V
.
CO2 ) ratio (V
.
E/V
.
CO2 
slope), has also been shown to have prognostic power.  The V
.
E/V
.
CO2 slope is an effort-
independent variable. It has been shown to correlate with cardiac output, left ventricular 
filling pressures, and ventilation perfusion mismatching (Tomkiewick-Pajak et. al., 
2002). Although more recent studies have shown that the V
.
E/V
.
CO2 slope may be a more 
sensitive predictor of major cardiac events in patients with CHF (Arena et al, 2004; Bard 
et al., 2006), it has not received as much attention in the literature as V
.
O2peak. Therefore, 
it has not yet gained the same clinical acceptance. 
 Despite its widespread use, a common criticism of V
.
O2peak is that it is effort-
dependent and thus can be influenced by patient motivation (Myers et al., 2000; Ramos-
Barbon et al., 1999). Hence, having a way to ensure that patients are tested at their 
maximal effort level is important in order to generate meaningful CPX data. 
 While several criteria exist for assessing a maximal exercise effort, including a 
plateau in V
.
O2 with increased work rate, previous studies have shown that peak 
respiratory exchange ratio (V
.
CO2/V
.
O2) (RERpeak) is a simple and useful objective 
criterion of effort (Howley et al., 1995; Mezzani et al., 2003). There is debate as to the 
optimal RERpeak cut point for identifying a maximal effort. Several studies have 
suggested an RERpeak of 1.10 (Issekutz et al., 1961; Neuberg et al., 1988; Fleg et al., 
2000; Arean et al. 2004;  American College of Sports Medicine, 2006) while other 
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authors have suggested a higher cut point of at least 1.15 (Mezzani et al., 2003; Corra et 
al., 2004). However, Aitken et al. (1988) demonstrated that not all subjects attain an 
RERpeak >1.15, even when they reach a V
.
O2 plateau. Based on established guidelines, an 
RERpeak >1.10 is commonly accepted to be indicative of a maximal effort (American 
College of Sports Medicine, 2006). 
 In clinical experience, a significant proportion (~50%) of patients with heart 
failure are often unable to attain an RERpeak >1.10 (unpublished results, HF Action 
database, LeBauer Cardiovascular Research Foundation). This may be attributable to 
certain muscular abnormalities such as lower active skeletal muscle mass (Anainsson et 
al., 1981), gradual diffusion of acid metabolites from active skeletal muscle into the 
blood stream (Shephard et al., 1975), and some ventilatory abnormalities due to 
respiratory muscle fatigue.  
Currently, there is controversy about the predictive value of CPX testing in CHF 
patients with low RERpeak and whether or not it may be possible to identify the significant 
predictors of CHF-related events within low RERpeak group with RERpeak <1.10. 
Furthermore, it is not yet evident if other variables, including V
.
E/V
.
CO2 slope derived 
from CPX testing, age, sex, body mass index (BMI), left ventricular ejection fraction 
(LVEF), etiology of CHF (ischemic or non-ischemic), and beta-blocker usage have an 
ability to predict the rates of major heart failure events in CHF patients with low RERpeak 
for a given V
.
O2peak.  
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Purpose of the Study: 
The purpose of this study is to determine if specific variables assessed from 
―maximal‖ CPX testing can be used to predict future major heart failure events (LVAD 
implantation, heart transplantation, or death) in CHF patients with systolic dysfunction 
who have not undergone previous LVAD implantation or heart transplantation.  
 
Specific Aims:  
1. After stratifying CHF patients by V
.
O2peak (<14 ml/kg/min vs. >14 ml/kg/min), 
examine the effects of RERpeak (<1.10 vs. >1.10) on the survival probability for major 
heart failure events over a two-year period.   
2a. Among those with a low RERpeak within each V
.
O2peak stratum, perform bivariate  
 survival analyses examining the effects of the following independent variables 
(considered one at a time) on two-year survival probability for major heart failure 
events: V
.
E/V
.
CO2 slope (low/high), age (young/old), sex (male/female), BMI (non-
obese/obese), LVEF (low/high), CHF etiology (ischemic/non-ischemic), and beta-
blocker use (yes/no). 
2b. Based on the bivariate analyses in Aim 2a, identify the subgroups with the 
statistically significant lower survival probabilities within the low RERpeak group and 
compare to the high RERpeak group within the same V
.
O2peak stratum.   
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Working Hypotheses:  
1. Within each V
.
O2peak stratum, CHF patients with a low RERpeak will have a higher 
probability of survival than patients with a high RERpeak. This will likely be due to a 
portion of the low RERpeak patients failing to exercise at a maximal effort. 
2a. In CHF patients in low RERpeak group for a given V
.
O2peak stratum, the following 
groups of patients will have a lower probability of survival: higher V
.
E/V
.
CO2 slope, 
older age, lower LVEF, ischemic etiology of CHF, and beta blocker non-users. There 
is little previous research comparing the survival probability for major heart failure 
events between male versus female and obese versus non-obese patients. Therefore, 
the analyses of these variables are exploratory in nature and no hypotheses 
concerning them have been generated.  
2b. Within each V
.
O2peak stratum, the subgroups of low RERpeak identified in Aim 2a as 
having significantly lower survival probabilities for CHF events will have similar 
probabilities of survival as the high RERpeak group.  
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
  
This section will discuss the parameters of cardiopulmonary exercise (CPX) 
testing and will review the research that examined the impact of CPX and other 
physiologic derived variables on major heart failure events in congestive heart failure 
(CHF) population. There will be particular focus on peak oxygen consumption (V
.
O2peak), 
the respiratory exchange ratio (RER), and the slope of minute ventilation to CO2 
produced (V
.
E/V
.
CO2 slope).  
 
Congestive Heart Failure 
CHF is a leading cause of mortality and morbidity and is a public health challenge 
worldwide. This is related to epidemic increases in hypertension, atherosclerosis, obesity, 
diabetes, and valvular abnormalities in which CHF is generally the end stage of the 
disease (Young et al., 2004). According to the American Heart Association 2004 update 
on heart disease and stroke statistics, CHF affects approximately 5 million Americans 
and 15 million people worldwide.  
Due partly to advanced therapeutics and a rapidly growing aging population, an 
increased life span of cardiac patients has contributed to an increased prevalence of CHF.  
CHF has become the major leading cause of hospitalization in older adults
 7 
(Kannel et al., 2000). More than 75% of the patients in US are older than 65 years (Rich 
et al., 1997). The number of hospital admissions for CHF increased to approximately 1 
million in 2004. This has imposed an immense financial burden on the health care system 
in the US, as more than $30 billion is spent each year for the care of heart failure patients 
(Rosamond et al., 2007).  
CHF is defined as an inability of the heart to maintain or increase cardiac output 
at a rate commensurate to the aerobic requirements of the body (Fleg et al., 2000). As a 
result, patients with CHF often experience fatigue and dyspnea with exertion and, in the 
most advanced cases, dyspnea at rest. Not surprisingly, many of these patients develop 
difficulties performing their activities of daily living. CHF has two types: systolic and 
diastolic. Systolic heart failure, which represents approximately 50% of CHF cases, 
results from abnormalities in the contractile capacity of the heart due to the loss of 
functional myocardium. This results from myocardial infarction, an excessive preload 
affecting the pumping capacity of the heart (e.g.valvular regurgitation), an increased 
afterload (e.g. hypertension), and heart rate disturbances affecting duration of 
contractility. Diastolic heart failure results from abnormalities in the relaxation of the 
heart due to cardiac muscle hypertrophy, impaired compliance, and aging. This is seen 
with myocardial composition disorders that stiffen the heart chambers. CHF is also 
divided according to etiology into ischemic cardiomyopathy (ICM) and non-ischemic 
cardiomyopathy (NICM). ICM is defined as myocardial dysfunction due primarily to 
ischemic injury. In many patients with ischemic myocardial injury, left ventricular 
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remodeling occurs. This involves necrosis of cardiomyocytes, weakening of the 
myocardium due to inflammation, formation of a collagenous scar, and dilation and 
hypertrophy of the ventricle (Sutton et al., 2000). This often leads to ventricular wall 
weakness, increased ventricular load, distortion of the contractile capacity of the heart, 
and a decrease in left ventricular ejection fraction (LVEF). NICM includes heart diseases 
resulting from idiopathic, postpartum, peripartum, alcoholic, hypertrophic, restrictive, 
and valvular causes, as well as drug toxicity, viral and infiltrative disorders. These 
etiologies ultimately lead to dilation of the left ventricle as a compensatory mechanism to 
increase LVEF.   
It is important to assess the functional capacity of CHF patients to tailor 
pharmaceutical and/or surgical therapy. Cardiopulmonary exercise (CPX) testing is an 
essential standard tool to assess functional capacity in ambulatory CHF patients.  
 
Causes of Exercise Intolerance in CHF:  
CHF patients generally terminate exercise testing due to the development of leg 
fatigue and/or abnormal ECG changes which may be caused by ischemia (due to 
compromised cardiac output). They may also stop CPX testing due to exertional dyspnea 
or leg fatigue. Previously, it was believed that the severity of exercise intolerance in CHF 
patients was solely related to hemodynamic impairment, but it is now known that causes 
of exercise intolerance are more complex. Abnormalities in central (cardiac), ventilatory 
and peripheral factors affect exercise capacity in CHF patients.  
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Central factors include: 1) systolic dysfunction due to impaired contractility, 2) 
diastolic dysfunction due to impaired compliance, 3) elevated pulmonary venous pressure 
affecting ventricular output and hence systemic blood flow during exercise, and 4) 
reduced beta-adrenergic receptor density and its desensitization, causing abnormal 
neurohumoral responses during exercise (i.e., chronotropic and inotropic incompetence) 
(Myers et al.,1991).  
Ventilatory factors contribute mainly to exertional dyspnea in CHF. These 
include: 1) increased physiologic pulmonary dead space due to ventilation-perfusion 
mismatch [this leads to an increased ratio of total dead space to tidal volume (V
.
d/ V
.
t)] 
and 2) increased ratio of minute ventilation to carbon dioxide produced (V
.
E/V
.
CO2). It 
increases ventilation through intact neural and chemoreceptor mediated reflexes (Sullivan 
et al., 1988). Exertional dyspnea can also be attributed to increased pulmonary capillary 
wedge pressure. It reduces lung compliance and stimulates pulmonary juxtacapillary 
receptors. Thus, it ultimately enhances ventilation and produces abnormal ventilatory 
control, and breathing pattern (Myers et al., 1991). Abnormalities of ventilatory muscles, 
such as decreased respiratory muscle strength and work, increased diaphragmatic work 
and accessory respiratory muscle deoxygenation or bronchial hyper reactivity, also cause 
exertional dyspnea (Mancini et al., 1992; Cabanes et al., 1989).  
Peripheral factors, such as vascular and muscular impairment, are major 
contributors to exertional fatigue in CHF. Abnormal vasomotor tone has been observed in 
CHF patients, especially in the resistance vessels of skeletal muscle due to increased 
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sodium content and increased tissue pressures seen in edematous states (Zelis et al., 
1975). This can lead to a decreased vasodilatory response to exercise- or ischemia-
induced metabolites and increased peripheral resistance due to enhanced ergoreceptor 
activity (Clark et al., 1996). The decreased skeletal muscle circulation results in increased 
oxygen extraction [(a-v
_
)O2 difference] as a compensatory response (Myers et al., 1991). 
However, the increased oxygen extraction does not fully make up for the decreased blood 
supply. The resulting compromise in oxygen supply results in an earlier onset of 
anaerobic glycolysis, producing excess lactic acid and metabolic acidosis (Zelis et al., 
1975). However, Massie at al. (1987) demonstrated that, although CHF patients have 
significantly lower pH at submaximal levels of exercise compared to normal controls, 
this is not associated with blood supply to muscles or muscle atrophy. Instead it is 
attributed to abnormalities within the skeletal muscle itself. In CHF patients, skeletal 
muscles show metabolic and histological abnormalities due to disease related pathology, 
including inactivity and/or chronically impaired circulation. Metabolic abnormalities 
include earlier onset of glycolysis, decrease in oxidative phosphorylation and 
mitochondrial enzymes (Mancini et al., 1988; Clark et al., 1996). Histological changes 
include skeletal muscle atrophy resulting from deconditioning, inactivity or malnutrition 
(Mancini et al., 1988), intramuscular lipid accumulation (Clark et al., 1996), reduction in 
type-I slow twitch fibers with high oxidative capacity and increase in type-IIb fast twitch 
fibers with reduced aerobic capacity (Myers et al., 1991; Clark et al., 1996). These 
vascular and musculoskeletal abnormalities contribute to exertional fatigue. These 
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histochemical abnormalities are also suspected to involve respiratory muscles causing 
early respiratory fatigue and dyspnea.  
 
Purpose of Cardiopulmonary Exercise Testing in CHF Patients:  
CPX testing is a standard modality of integrative measurement of the 
hemodynamic, ventilatory and musculoskeletal systems. During CPX testing, a gradually 
increasing physiological stress is induced. CPX testing is conducted with careful 
monitoring of the patients and both objective and subjective measurements. CHF patients 
generally present with dyspnea and/or fatigue. This often limits their daily activities and, 
in worse cases, self-care. Hence, it is important to measure the functional capacity of 
CHF patients to assess the extent of their impairment. Patients with heart failure often 
demonstrate normal cardiac performance at rest. Therefore, measures of left ventricular 
performance obtained at rest do not correlate well with functional capacity (Franciosa et 
al., 1981). Physiological stress, such as exercise, is usually needed to determine the extent 
of functional impairment (Weber et al., 1982).  
Standard CPX testing includes the measurement of ventilation and expired gases 
to determine oxygen uptake (V
.
O2), carbon dioxide production (V
.
CO2), respiratory rate, 
tidal volume (V
.
t) and minute ventilation (V
.
E) during graded exercise. Other important 
variables include: total exercise duration within a given exercise protocol, maximal 
oxygen uptake (V
.
O2max), ventilatory efficiency denoted by slope of minute ventilation to 
CO2 production (V
.
E /V
.
CO2 slope), respiratory exchange ratio (RER), heart rate (HR), 
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blood pressure, and oxygen saturation (SaO2). Additionally, subjective parameters, such 
as rating of perceived exertion (RPE), can be obtained. These CPX parameters will be 
explained in the next section. Many of them have been suggested as diagnostic or 
prognostic markers, independently or in combination with each other, in the heart failure 
population.  
CPX testing is a cost-effective and non-invasive clinical tool. Accurate 
interpretation of clinical data obtained from CPX testing helps to determine the severity 
of CHF. This enables clinicians to determine a prognosis (Corra et al., 2004), decide 
therapeutic options, and assess the efficacy of the treatment provided. CPX also helps in 
differentiating whether dyspnea and fatigue are of cardiac or pulmonary origin (Neuberg 
et al., 1988). Most importantly, CPX testing plays a crucial role in deciding when to refer 
CHF patients for advanced therapies, such as left ventricular assistive devices (LVADs) 
and heart transplantation (Myers et al., 1998). Given the scarcity of donor organs and the 
costs associated with treating advanced heart failure, the ability to accurately identify 
patients who are at the highest risk for adverse outcomes is crucial.  
 
Determination of Maximal Aerobic Capacity:  
In order to precisely establish their diagnosis and prognosis, it is important that 
CHF patients give maximal efforts during CPX testing to determine reliable measures of 
cardiorespiratory reserve. However, many CHF patients do not yield ―maximal‖ values in 
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some testing variables despite giving maximal effort. Therefore, accurate and objective 
criteria are needed to determine whether V
.
O2max is reached during exercise.  
It has been demonstrated that there is a certain upper limit to the combined 
functional capacity of the cardiovascular and respiratory systems to transport oxygen to 
the working muscles. A linear relationship exists between V
.
O2 and the increase in work 
load until a certain point. Beyond this point, there is no increase in the oxygen uptake in 
spite of an increasing work load. This is defined as V
.
O2plateau (Hill, 1926). Reaching a 
plateau in oxygen uptake with increased work rate is considered the gold standard 
criterion for V
.
O2max (Howley et al., 1995). The V
.
O2max achieved serves as an indicator of 
the maximal cardiovascular capacity provided that pulmonary function is normal. Hence, 
it plays a vital role in the diagnosis and prognosis of patients with impaired 
cardiovascular health. V
.
O2max depends not only on the mechanical capacity of the heart to 
perform but also on the ability to increase (a-v
_
)O2 difference, which reflects the capacity 
of peripheral tissues to extract oxygen from the circulation (Mitchell et al., 1958).  
Many problems exist with the use of V
.
O2 plateau as a consistent criterion for 
maximal effort. It is open to inter-subject variability depending upon differences in the 
criteria used for its definition, protocol used (intermittent versus continuous), methods of 
data collection by automated systems, and interval sampling of the data (Myers et al., 
1990), inability of everyone to achieve a V
.
O2 plateau, health, age, motivation, and safety 
of continued work at a maximal level (Myers et al., 1989; Howley et al., 1995; Sidney et 
al., 1977).  
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Historically, different cut-off values have been suggested as the criteria for 
establishing V
.
O2 plateau such as (Howley et al., 1995): an increase of V
.
O2 <150 
ml/kg/min or <2.1 ml/kg/min when treadmill grade is increased by 2.5% per 3min stage 
at 7mph (Taylor et al., 1995), <54 ml/min when grade is increased by 2.5% at 6mph per 
2.5 min stage (Mitchell et al., 1958), <2 ml/kg/min with a 1-2 % increase of treadmill 
grade (Sideny et al., 1977), <100 ml/min when cycling work load is increased by 150 
kpm/min (Issekutz et al., 1961), and <50 ml/min when subject is tested with an 
intermittent cycle ergometer test until workload could not be maintained for 3 minutes 
(Cumming et al., 1967). These studies used different equipments and protocols. Although 
it is commonly accepted that failure to increase oxygen uptake by 150 ml/min with 
increased work load is the plateau of oxygen uptake (Froliecher and Myers, 2000), a cut-
off value has not yet been universally accepted.  
Secondly, it may not be possible for everyone to achieve V
.
O2 plateau (Wyndham 
1959). Previous studies show different percentages of study populations reaching true  
V
.
O2 plateau as 50% (Cumming et al., 1967), <40% (Froelicher et al., 1974) and 70% 
(Sideny et. al., 1977). In 1989, Myers et al. tested healthy subjects and demonstrated that 
occurrence of plateau is not a consistent observation with repeated testing, even when 
maximal heart rate, perceived exertion, and maximal gas exchange parameters were high 
and unvaried.  
It is difficult for low fit, elderly, and low motivated individuals to reach V
.
O2 
plateau as attainment of the plateau requires high subject motivation (Hollenberg et al., 
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2000; Sidney et al., 1977). The protocol used also affects the percentage of subjects 
achieving true V
.
O2 plateau and seen as 33% in Taylor protocol, 17% in Balke protocol 
and 7% in Bruce protocol (Froelicher et al., 1974). This can be affected by large work 
rate increments. Intermittent protocol or repeat testing increases the number of subjects 
reaching V
.
O2 plateau (Taylor et al., 1955; Sidney et al., 1977).   
The reliability and consistency of a plateau is questioned in the heart failure 
population, as many CHF patients are deconditioned due to disease and old age. They 
also have reduced daily activities due to symptoms, muscular weakness, poor motivation, 
and fear of untoward complications of the disease (Sideny et al., 1977). It is difficult to 
make elderly patients work up to and sustain their maximal levels due to the anaerobic 
stress produced (Cumming et al., 1972).  
Alternatively, the concept of peak oxygen consumption (V
.
O2peak) has been 
considered where subject reaches the point of fatigue even in absence of plateau in 
oxygen uptake. It is important to determine whether V
.
O2peak denotes a maximal effort or 
not. Hence, certain secondary criteria are developed to help determine if a subject has 
given a maximal effort. These criteria include: high post-exercise blood lactate 
concentration, achievement of a certain percentage of age adjusted maximal heart rate 
and/or exercise capacity, high RER, and high RPE (Howley et al., 1995).  
Many of these criteria have limitations associated with their use. For example, 
obtaining post-exercise lactate response requires blood sampling. In addition, previous 
researchers have shown variability in post-exercise lactate values obtained as maximal 
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effort criteria, such as: 7.3 mM (Issekutz et al., 1961), increase by at least 60 mg/100ml 
above pre-exercise level (Issekutz et al., 1962), 5.5 mM (Doblen et al., 1967), >8 mM 
(Cumming et al., 1972), and 8.8 mM (Sidney et al., 1977). Blood lactate level of >7-8 has 
been traditionally considered as a concensus index of maximal effort (Froliecher et al., 
2000). A lower percentage of the elderly population can reach this standard (Sidney et al., 
1977; Cumming and Borysk, 1972).  Lactate levels are also shown to be higher in men 
than women (Sidney et al., 1977). This can be attributed to a higher ratio of muscle mass 
to total blood volume in men compared to women. This ratio also results in decreased 
maximal lactate concentration with aging. Therefore, the lactate responses vary across 
subject populations, age groups and protocols used and should not be held as a universal 
standard of maximal effort (Howley et al., 1995). 
Achievement of some percentage of age-adjusted maximal heart rate is also 
considered as a secondary criterion to determine V
.
O2max level. The standard deviation 
associated with the maximal HR estimate is +11 beats/min (Londeree et al., 1984), which 
reflects large inter-subject variability (Cumming et al., 1972). In addition, this criterion is 
not useful with patients on beta-blocking drugs and other medications that affect HR, 
which are very common among CHF patients. Ramos-Barbon et al. (1995) observed that 
50% of CHF patients with VO2peak <14 ml/kg/min did not achieve >85% of the 
HRpeak/HRpredicted, indicating chronotropic limitation. Hence, they suggested the need for 
other objective criteria to confirm maximal effort in performing precise risk stratification 
in CHF patients with low V
.
O2peak.  
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The Borg RPE scale consists of subjective patient-reported fatigue ratings ranging 
from 6 (very, very light) to 20 (very, very hard). A high RPE level (>17) achieved at the 
end of the exercise is considered as the attainment of maximal effort (American College 
of Sports Medicine, 2006). However, this criterion is highly subjective, which can skew 
the accuracy of maximal effort measured.  
Finally, RER measured at the peak of exercise (RERpeak) is another secondary 
criterion for the attainment of maximal effort.  It is objective and is determined by gas 
exchange parameters collected during CPX testing. Hence, it is widely used to determine 
if maximal effort level is achieved. 
 
Respiratory Exchange Ratio: 
Respiratory exchange ratio is defined as the amount of CO2 produced divided by 
amount of O2 consumed (Froelicher and Myers, 2000). The cellular counterpart of RER is 
the metabolic respiratory quotient (RQ), which is calculated as Q
.
CO2/ Q
.
O2 where Q
.
O2 is 
O2 consumption by the cells and Q
.
CO2 is CO2 production by the cells. RQ reflects 
metabolic exchange of gases at the cellular level and is dictated by substrate utilization. 
RQ measured from arterial blood gases is 0.2 times higher with a high carbohydrate diet 
than with a high fat diet (Wasserman et al., 1967). RER is related to but not equivalent to 
RQ, as RER reflects RQ only at the steady state, where no CO2 is being added to or 
removed from the body CO2 stores and O2 body stores remain constant. At higher 
exercise intensities, RER exceeds metabolic RQ due to acute hyperventilation and acute 
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metabolic acidosis. In the latter case, excess CO2 is produced through the buffering of 
lactic acid with bicarbonate (Wasserman, 1994). 
 
Mechanism of RER Increase with Maximum Graded Exercise:  
Resting RER value ranges from 0.70-0.85. At higher exercise work rates 
(RER>1.0), metabolic demands of working muscle exceed the O2 supply. This increases 
anaerobic glycolysis, leading to plasma accumulation of lactic acid.  In turn, hydrogen 
ions (H
+
) dissociate from lactate and are buffered through the carbonic anhydrase 
reaction:  
H
+
 + HCO3
-
   ↔   H2CO3   ↔   H2O + CO2  
The reciprocal relationship between arterial plasma bicarbonate and lactate 
concentration has been identified at each work intensity by Wasserman et al. (1967). As 
production of CO2 increases, it sensitizes carotid chemoreceptors to increase ventilation 
(Neuberg et al., 1988), which acts as a respiratory compensation to regulate the pH 
(Howley et al., 1995). As explained by Wasserman (1994), increased CO2 production and 
increased ventilation augments CO2 delivery at the lungs, raising V
.
CO2 with progressive 
exertion. This increase in V
.
CO2 exceeds the increase in V
.
O2, as hemoglobin is saturated 
with O2 at the pulmonary capillary level. This leads to an increase in V
.
CO2/ V
.
O2. In CHF 
patients, delivery of O2 to the tissues in response to increased metabolic need is impaired 
due to reduced cardiac output. This also promotes anaerobic glycolysis and accumulation 
of lactic acid leading to increased RER (Weber et al., 1982).  
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The magnitude of anaerobic glycolysis during exertion is also related to the types 
of muscle fibers recruited. Below the anaerobic threshold, type slow-twich (Type I) fibers 
of high oxidative capacity are primarily recruited and fatty acids are utilized as the major 
fuel. Above the anaerobic threshold, the recruitment of fast-twich (Type II) fibers of low 
oxidative capacity increases. In these fibers carbohydrate is utilized as the major fuel and 
anaerobic glycolysis predominates as mitochondrial density is lower (Wasserman, 1994; 
Neuberg et al., 1988). In CHF, it is possible that abnormalities of skeletal muscle fiber 
structure and function can interfere with the capacity to work at higher levels. This may 
result in different RERpeak values in conditions affecting above components.  
Variable RER Values at Peak Exercise:  
Previous research has considered variable values of RERpeak to indicate maximal 
effort, such as: RERpeak >1 (Clark et al., 1994), >1.10 (Neuberg et al., 1988; Chua et al., 
1996; Chua et al., 1997; Hollenberg et al. 2000), >1.12 (Cumming et al., 1972), and 
>1.15 (Sidney et al., 1977). Although RERpeak >1.10 has been traditionally considered as 
subsidiary evidence of attainment of VO2max in the CHF population (Fleg et al., 2000), 
RERpeak values vary greatly and an accurate physiologic cut-off point to confirm maximal 
effort is hard to define (Froelicher and Myers, 2000).  
Historically, many researchers have studied the changes in RER from rest to 
maximal exercise and established different values of RERpeak as a secondary criterion of  
V
.
O2max. In 1961, Issekutz et al. tested healthy adults by a series of intermittent exercise 
sessions on a bicycle ergometer for 4-5 minutes until V
.
O2max was achieved. Gas 
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exchange data was collected throughout exercise and the lactate levels were measured 1-2 
minutes post-exercise. They calculated excess (non-metabolic) CO2 at the end of exercise 
(excess CO2= total CO2  - 0.75 * VO2) where true metabolic respiratory quotient (RQ) 
was assumed to be 0.75. A linear relationship existed between the excess CO2 and change 
in lactate levels (correlation coefficient, r = 0.92). This excess CO2 was expressed as  
∆RQ (calculated as measured RQ - 0.75) which supposedly resulted from a delayed 
circulatory response in the early phase and increased lactate concentration in late phase of 
graded exercise, with the latter representing percent participation of anaerobic glycolysis 
in total energy expenditure.    
In 1962, Issekutz et al. again tested healthy adults on a bicycle ergometer with 
series of intermittent tests of 5 minute duration until V
.
O2max was achieved. They 
calculated ∆RQ (ratio of excess CO2/O2= work RQ – 0.75) and observed that each 
subject (at least above 20 years of age), independent of age and sex, reached V
.
O2max 
when the RQ was 1.15 or higher. This implicated that ∆RQ of 0.4 or RQ of >1.15 
(0.75+0.4) can be used as secondary criterion of VO2max. But this method had certain 
drawbacks (e.g., exercise mode was limited to cycle ergometry).  Hence, application of 
these results to treadmill CPX testing can be questioned. Similarly, the population 
included in this study was healthy and thereby limits the general applicability of the 
results to diseased populations. Also, the subjects underwent intermittent testing instead 
of continuous testing as is practiced currently. Even though it is agreed that V
.
O2max 
remains the same across continuous and discontinuous protocols (McArdle et al., 1973), 
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lactate (Shephard et al., 1968) and RERpeak (McArdle et al., 1973) values differ with 
application of continuous and discontinuous protocols.  
Howley et al. (1995) has discussed the studies with different RERpeak. An RERpeak 
value of <1.0 has been observed to be associated with low lactate values (Cunningham et 
al., 1977). However, Cumming et al. (1972) observed no correlation between RERpeak and 
post-exercise lactate. RERpeak of >1.15 as a maximal effort criterion has been questioned 
as it has also been observed that not all subjects can reach RERpeak >1.15 even though 
they attain V
.
O2 plateau.  Hence, this value can not be considered as a universal criterion 
for V
.
O2max. Other researchers have observed different values of RERpeak achieved at  
V
.
O2max. Robinson et al. (1938) demonstrated that RERpeak >1.15 can be an indicator of  
V
.
O2max between 20-60 years, but younger subjects (6-19 years) failed to achieve this 
standard. In addition, Cumming et al. (1972) tested 40-65 year-old males and females. 
They observed that mean maximal exercise RER was 1.13 and only 54% of their subjects 
could reach RERpeak >1.12. Aitken and Thompson (1988) tested individuals of variable 
age groups and fitness levels. This study illustrated an RER range of 1.01-1.11 at V
.
O2max. 
None of the tested groups reached RERpeak >1.15. Sidney et al. (1977) compared RER 
values obtained at peak exercise (volitional fatigue) between apparently healthy men and 
women between the ages of 60 and 83 years. Only 37 % of men and 20% of women 
reached an RERpeak >1.15. Also, RERpeak in women (1.07+0.09) was lower than in men 
(1.11+0.08). The studies mentioned in this paragraph used the treadmill for exercise 
testing except Cumming et al. (1972) who used the bike ergometer. 
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In summary, several previous studies have documented RERpeak values lower than 
the traditional criterion of >1.15 at maximal effort. A significant amount of this research 
has been performed in age groups that encompass the majority of the CHF population. 
Hence, exploration of a lower RERpeak cut-off to signify maximal effort is warranted. 
Low RERpeak in CHF Patients: 
A significant proportion of patients with heart failure are unable to attain a plateau 
of V
.
O2 or a RERpeak >1.10. Thus, it has been argued that CPX testing does not provide a 
reliable assessment of prognosis for this group due to the ―submaximal‖ nature of the 
exercise. 
Previous researchers have found that several factors affect RERpeak. Sidney et al. 
(1977) observed lower post-exercise lactate levels with increasing age and also in 
females, which can be attributed to lower ratio of muscle mass to total blood volume. 
Aitken et al. (1988) demonstrated RERpeak at V
.
O2max to be significantly lower in older 
sedentary subjects (>60 years) when compared with young sedentary controls. This age-
related decrease in RERpeak may be attributed to several factors including different 
protocols used for young subjects (running level on treadmill) and old subjects (walking 
protocol on level treadmill), age related reduction in active skeletal muscle mass, 
decrease in Type II muscle fibers (Anainsson et al., 1981), lesser amount of glycogen 
reserve per unit muscle mass, gradual diffusion of lactic acid metabolites from the active 
skeletal muscle into the circulation leading to low levels of end stage blood lactate and 
high levels of local muscle lactate (Shephard et al., 1975), and respiratory muscle fatigue. 
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As CHF is typically a disease of the elderly (Rich et al., 1997), lower RERpeak values can 
be predicted in this population when compared with normal subjects. In conclusion, 
RERpeak shows considerable inter-individual variability. It is important to determine if 
selected CHF patients with lower RERpeak for a given V
.
O2peak peak still warrant 
consideration for heart transplantation and LVAD implantation.  
RERpeak And Prognosis in CHF:   
RERpeak ranging between 1.10-1.20 is generally considered as an index of 
maximal effort in healthy subjects (Frolicher and Myers, 2000). Yet it is not quite clear to 
what extent RERpeak reflects maximal effort. This impacts the prognostic power of other 
exercise variables such as V
.
O2peak and V
.
E/ V
.
CO2 slope in CHF population. Some recent 
studies have tried to establish the role of RERpeak as a measure of subject effort and its 
contribution to prognostic power of V
.
O2peak and V
.
E/ V
.
CO2 slope.  
Conflicting data exist regarding the relationship between RERpeak and cardiac 
related events in CHF patients. Gitt et al. (2002) tested CHF patients and followed them 
(median follow-up time of 1.76 years) to identify prognostic indicators for survival. They 
observed that RERpeak was not significantly different among survivors and non-survivors 
(1.07+0.13 vs. 1.04+0.14 respectively). Mezzani et al. (2003) demonstrated that the 
prognostic significance of low V
.
O2peak in CHF patients gets compromised when the RER 
attained at the last stage of exercise is low. They observed that, in patients who attained  
V
.
O2peak <10 ml/kg/min on maximal exercise testing, the ability to attain RERpeak of >1.15 
was seen as the only independent predictor of mortality and transplantation with a 
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relative risk of 1.65. The percentage of patients achieving RERpeak >1.15 was 
significantly higher in the CHF event group than in the survivors (65% vs. 39%). When 
these patients were further stratified based on RERpeak, those with RERpeak <1.15 had a 
two-year survival rate of 83% which is comparable to patients with V
.
O2peak >14 
ml/kg/min, while those with RERpeak >1.15 had significantly lower two-year survival rate 
of 52%. This study indicated that RERpeak affects the prognosis in CHF patients with very 
low V
.
O2peak (<10 ml/kg/min). Hence, they suggested that patients in this group should be 
encouraged to exercise until RERpeak reach >1.15 and a cautious decision must be made 
when RERpeak is <1.15. However, they did not observe any impact of RERpeak on 
prognostic power of V
.
O2peak in the subgroup of patients with V
.
O2peak 10-14 ml/kg/min 
and suggested that V
.
O2peak of >10 ml/kg/min is associated with better aerobic capacity 
and prognosis is independent of achievement of maximal effort as denoted by two-year 
survival rate of 89% in this group.   
Conversely, a study by Arena et al. (2004) observed that the submaximal subject 
effort impacts prognosis in CHF patients wherein low RERpeak (<1.10) influences the 
prognostic power of both the variables: V
.
O2peak and V
.
E/ V
.
CO2 slope. They tested CHF 
patients where maximal effort was considered as RERpeak >1.10. The 1-year event rate 
(cardiac related hospitalization and cardiac related mortality) was 27% in the <1.10 
RERpeak subgroup and 32% in >1.10 RERpeak subgroup. The analysis showed that both  
V
.
O2peak and V
.
E/ V
.
CO2 slope were significant predictors of cardiac related events in both 
maximal and submaximal RERpeak subgroups. However, the prognostic value for  
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V
.
E/ V
.
CO2 slope was consistently higher than those of V
.
O2peak in both RERpeak 
subgroups.  
A review by Howley et al. (1995) showed that almost all of the studies in healthy 
subjects used an RERpeak of 1.0 to 1.05 as a cut off value for V
.
O2max determination. 
Hence, the guidelines for the care of cardiac transplant candidates published in 2006 
mentioned that RERpeak of >1.10 may be a very strict criteria for CHF patients (Mehra et 
al., 2006). According to these guidelines, class I criteria of listing CHF patients for heart 
transplantation include V
.
O2peak of <14 ml/kg/min (in absence of beta-blockers) and <12 
ml/kg/min (in presence of beta-blockers) whereby CPX test is defined maximal when 
patients achieve RERpeak >1.05. But it is possible that all CHF patients, especially the 
severely impaired, may not be able to achieve RERpeak of >1.05. Further, while stating an 
RERpeak cut-off of >1.05 for maximal effort, these guidelines do not include experimental 
evidence examining the effects of low RERpeak on CHF events. 
In summary, these previous studies do not show uniform findings concerning the 
prognostic impact of RERpeak in the CHF population. Since most CHF patients present a 
V
.
O2peak range from 10-18 ml/kg/min it is important to stratify this V
.
O2peak range and 
assess the impact of RERpeak on the prognosis in CHF patients.  
RERpeak values also vary according to etiology of CHF (ischemic versus non-
ischemic). Arena et al. (2005) observed that overall RERpeak was significantly higher in 
CHF patients with ischemic etiology when compared with non-ischemic etiology 
(1.12+0.18 vs. 1.07+0.15). RERpeak was also significantly higher in the event-free group 
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of ischemic etiology than the event-free group of non-ischemic etiology (1.13+0.17 vs. 
1.08+0.15). But the difference in RERpeak was not significantly higher in patients with 
cardiac related events in ischemic etiology than with non-ischemic etiology (1.12+0.18 
vs. 1.05+0.17).   
Currently, little is known about the predictive value of CPX testing in CHF 
patients with low RERpeak. In low RERpeak groups, no conclusive information is available 
about probable prognostic indicators: V
.
E/ V
.
CO2 slope, age, sex, BMI, etiology of CHF, 
LVEF and beta-blocker use. Furthermore, it is not yet evident if the subgroup of low 
RERpeak with highest risk can be identified. This subgroup may have comparable risk to 
high RERpeak group for a given V
.
O2peak strata. Thus, further research can assist in the 
identification of subgroups in the CHF population of low RERpeak (<1.10), with lower or 
higher risk for events.  
 
V
.
O2peak: 
Currently V
.
O2peak is the most commonly used CPX testing parameter for 
assessing prognosis in CHF population. V
.
O2peak <14 ml/kg/min is the typical cut point in 
considering patients for cardiac transplantation (Mancini et al., 1991; Roul et al., 1994). 
A cornerstone study by Mancini et al. (1991) demonstrated V
.
O2peak as the major variable 
for risk stratification in CHF population. They showed that the survival rate for CHF 
patients with V
.
O2peak <14 ml/kg/min was significantly lower (48%) as compared to those 
with V
.
O2peak >14 ml/kg/min (94%) who were considered too well for transplantation due 
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to preserved exercise capacity. This study suggested that cardiac transplantation can be 
safely deferred in most ambulatory CHF patients with left ventricular dysfunction who 
have V
.
O2peak >14 ml/kg/min. Also, Chua et al. (1997) demonstrated that in CHF patients, 
V
.
O2peak was significantly lower in non-survivors as compared with survivors (14.0+6.8 
vs. 20.0+6.9). CHF patients of >70 years demonstrated V
.
O2peak as a significant prognostic 
predictor by univariate as well as by multivariate analysis (Davies et al., 2000). Mezzani 
et al. (2003) demonstrated that the two-year survival rate was 93% versus 75% in patients 
with V
.
O2peak >14 and <14 ml/kg/min respectively and was 89% versus 69% in patients 
with V
.
O2peak >10 and <10 ml/kg/min respectively. Osada et al. (1998) tested CHF 
patients and observed that 3-year survival rate was significantly lower in patients with  
V
.
O2peak <14 ml/kg/min than those with V
.
O2peak >14 ml/kg/min. Roul et al. (1994) 
prospectively tested 75 CHF patients with NYHA class II and III and grouped them into 
V
.
O2peak <14 ml/kg/min and V
.
O2peak >14 ml/kg/min. With a 1-year follow up they 
observed that prognosis was significantly worse in V
.
O2peak <14 ml/kg/min group as 
compared to V
.
O2peak >14 ml/kg/min. The importance of V
.
O2peak of <14 ml/kg/min as a 
prognostic indicator in CHF has also been supported by Gitt et al. (2000) indicating >3-
fold risk of early mortality within 6 months. 
In 2002, Corra and co-workers observed that the mortality rate was significantly 
higher in <10 ml/kg/min when compared with >18 ml/kg/min. But it was not 
significantly different between intermediate V
.
O2peak groups of >10 to <14 ml/kg/min and 
>14 to <18 ml/kg/min. Kao et al. (1997) also tested 178 CHF patients and observed 
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prognostic value of V
.
O2max in the intermediate risk group. They showed that patients with 
V
.
O2max of <12 ml/kg/min had significantly worse prognosis than those with V
.
O2max >17 
ml/kg/min and its prognostic value did not hold true for intermediate risk group with  
V
.
O2max of 12 to 17 ml/kg/min.  
Certain studies have demonstrated that the prognostic value of V
.
O2peak is 
established over a wide range and fail to recognize a single threshold value as prognostic 
marker. Myers et al. (1998) stratified V
.
O2peak in CHF patients as above and below 12, 14 
and 16 ml/kg/min where these levels demonstrated significant differences in risk for 
deaths but the degree of risk was similar at each of these levels. Also, in 2000, Myers et 
al. conducted another study including CHF patients and dichotomizing them according to 
V
.
O2peak levels above and below of 10,11,12,13,14,15,16 and 17 ml/kg/min. Their follow- 
up demonstrated that survival rate was significantly higher in the ―above‖ levels than the 
―below‖ levels for each of the above V
.
O2peak cut points. Each cut-off point of V
.
O2peak had 
the ability to differentiate survivors from non-survivors.  Therefore, the authors suggested 
using V
.
O2peak as a continuous variable to assess risk rather than establishing a particular 
threshold. Similarly Francis et al. (2000) demonstrated that low V
.
O2peak is a significant 
predictor of mortality in CHF patients and suggested that lower V
.
O2peak implies worse 
prognosis across range of 10-20 ml/kg/min, without single threshold.  
Limitations of V
.
O2peak as a prognostic indicator: 
Although V
.
O2peak has been used for risk stratification in CHF patients to 
determine optimal timing for cardiac transplantation (Mancini et al., 1991) and to assess 
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response to therapy, it has certain limitations. As measurement of V
.
O2peak is influenced 
by factors such as age, sex, muscle mass, deconditioning of the muscles, patient‘s 
motivation or body composition, some researchers have speculated that this variable may 
provide limited prognostic information. Even though many previous studies have 
demonstrated the prognostic significance of V
.
O2peak (<14 ml/kg/min) in CHF patients, 
Osman et al. (2000) indicated that V
.
O2peak adjusted for lean body mass is the better 
prognostic indicator than unadjusted V
.
O2peak and a cut off value of <19 ml/kg of lean 
body mass/min is considered to be a prognostic determinant of cardiac related death and 
urgent transplantation. This is because a substantial part of total body weight is fat which 
is much less metabolically active. V
.
O2peak is impacted by age related body fat changes 
and conditioning status and declines with age. Hence, it is advised to use lean body mass 
adjusted V
.
O2peak in CHF patients, especially women and obese patients, as a prognostic 
indicator.  
Many other studies tried to analyze the prognostic power of V
.
O2peak when 
combined with other variables in the CHF population. Chomsky et al. (1996) suggested 
using cardiac output and V
.
O2peak in combination to predict survival in CHF. Recently, the 
slope of minute ventilation to carbon dioxide (V
.
E/V
.
CO2 slope) during CPX testing has 
been suggested as an independent and strong predictor of prognosis in CHF (Corra et al., 
2004). Francis et al. (2000) demonstrated that low V
.
O2peak and high V
.
E/V
.
CO2 slope are 
equivalent and complementary predictors of mortality in CHF patients. Similarly, a study 
by Arena et al. (2004) in CHF patients demonstrated that V
.
O2peak and V
.
E/V
.
CO2 slope 
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were significant predictors of cardiac related events and when V
.
E/V
.
CO2 slope of >34 
was combined with V
.
O2peak <14 ml/kg/min, addition of V
.
O2peak improved the prognostic 
power of the V
.
E/V
.
CO2 slope to predict hospitalizations but not cardiac-related mortality. 
Undisputed significance of  V
.
O2peak: 
Despite the variable opinions of researchers, V
.
O2peak is still widely used in clinical 
decision-making. Patients with CHF are at a high risk of sudden cardiac death, hence it is 
important to identify the population at the highest risk to provide appropriate therapy. 
Due to increasing incidence of CHF, the demand of heart transplantation is increasing 
while the supply of donor hearts remains unchanged. This scarce availability of donor 
hearts requires careful selection of transplant recipients. As discussed above, the 
prognostic significance of V
.
O2peak has been established and, therefore, is accepted in 
clinical practice as a determinant of CHF treatment. Patients with V
.
O2peak <14 ml/kg/min 
are typically accepted as candidates for heart transplantation.  
To maximize the benefits of therapy, certain objective criteria are considered in 
determining if a patient gives maximal effort during exercise testing. A limitation 
observed with the V
.
O2peak studies discussed above is that they all used different 
indicators of maximal effort to verify V
.
O2peak. Also, no previous studies show clear 
evidence as to how the event rates would differ if CHF patients are grouped into low 
RER (<1.10) and high RER (>1.10) within a given V
.
O2peak stratum.  
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V
.
E/V
.
CO2  Slope:  
The relationship between minute ventilation (V
.
E ) and CO2 produced (V
.
CO2) is 
another important CPX derived parameter. The ratio of V
.
E/V
.
CO2 represents the 
ventilation required to clear CO2 produced by the body. Although CO2 is produced by 
both aerobic and anaerobic metabolism, V
.
CO2 is the amount of CO2 generated by the 
buffering of lactic acid attributable mainly to anaerobic stress generated during exercise. 
This accumulated CO2 sensitizes ventilatory reflexes increasing the ventilation to remove 
CO2. V
.
E/V
.
CO2 reflects acid-base balance, chemoreceptor sensitivity and breathing 
efficiency (Wasserman, 1994). In normal subjects, V
.
E and V
.
CO2 act parallel to each 
other. But in CHF patients, high V
.
E/V
.
CO2 values are observed due to abnormally high 
ventilatory responses (Froelicher and Myers, 2000). The V
.
E/V
.
CO2 ratio can be obtained 
at any time-point during exercise. Although it is a good prognostic variable and easy to 
calculate (Arena et al., 2002), it is subject to variability depending upon time-point at 
which it is calculated. The slope of the regression line relating V
.
CO2 to V
.
E (i.e., the  
V
.
E/V
.
CO2 slope) expresses the relationship between the increase of these variables (Chua 
et al., 1997). V
.
E/V
.
CO2 slope considers all the data-points from the beginning till the end 
of CPX testing. Hence, although it requires regression equation calculations, V
.
E/V
.
CO2 
slope is more linear, less variable (Arena et al., 2003), less susceptible to irregular 
breathing (Davies et al., 2000) and is effort independent (Arena et al., 2007). V
.
E/V
.
CO2 
slope is highly reproducible and inversely related to peak oxygen consumption (Chua et 
al., 1997).  
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An abnormally high V
.
E/V
.
CO2 slope has been considered as a factor indicating 
poor prognosis in CHF (Corra et al., 2004). It is an important predictor of mortality in 
CHF patients and is independent of age, peak oxygen consumption, NYHA class, 
exercise duration and LVEF (Chua et al., 1997). A high V
.
E/V
.
CO2 slope indicates that 
ventilation is increasing at a higher rate than V
.
CO2 produced. In CHF patients, high  
V
.
E/V
.
CO2 slope is associated with many central and peripheral factors such as: reduced 
cardiac output during exercise, increased pulmonary artery and pulmonary capillary 
wedge pressures, reduced pulmonary perfusion [which exacerbates ventilation-perfusion 
mismatching, leading to increased dead space/tidal volume ratio (Sullivan et al., 1988)], 
and enhanced hypoxic and central hypercapnic chemoreceptor sensitivity [which 
correlates significantly to increased ventilatory response during exercise in CHF patients 
(Chua et al., 1996)].  
Previous studies demonstrated that high V
.
E/V
.
CO2 slope is associated with high 
mortality in CHF patients. The major findings of this research are summarized in Table 1 
below:  
 
Study Findings 
Mezzani et al. (2003) When survivors were compared with non-survivors 
(death/ heart transplantation) in CHF patients with VO2peak 
<10 ml/kg/min, the event group had a significantly higher  
V
.
E/V
.
CO2 slope (45 +13 vs. 39 +8).  
 
Corra et al. (2002) When controlled for LVEF (<25 vs. >25%) and V
.
O2peak 
(<13 vs. >13 ml/kg/min), patients with V
.
E/V
.
CO2 slope of 
>35 had significantly higher mortality rate than those with  
V
.
E/V
.
CO2 slope of <35 (30% vs. 10% respectively). 
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Gitt et al. (2002)  CHF patients with a V
.
E/V
.
CO2 slope of >34 had a 5-fold 
increased risk of early mortality 
 
Chua et al. (1997) i. Included CHF patients who reached RER >1.10.  
 
ii. CHF patients with a normal V
.
E/V
.
CO2 slope (<34) had 
a significantly higher 1-year survival rate (98%) compared 
to CHF patients with a higher slope (>34, 73%). 
 
Table 1- Association of High V
.
E/V
.
CO2 Slope with High Mortality in CHF Patients 
 
V
.
E/V
.
CO2 slope has also proven to be a significant prognostic indicator in elderly 
CHF patients.   
 
Study Findings 
Davies et al. (2000) V
.
E/V
.
CO2 slope was a significant prognostic factor by 
univariate as well as by multivariate analysis in CHF 
patients >70 years. 
 
Cicoira et al. (2001) V
.
E/V
.
CO2 slope was a significant predictor of mortality in 
CHF patients >70 years. 
Table 2- Prognostic Value of V
.
E/V
.
CO2 Slope in Elderly CHF Patients 
 
It also has been established that a high V
.
E/V
.
CO2 slope alone or when combined 
with low V
.
O2peak acts as a better predictor of survival in CHF patients. It has been 
described in Table 3 below. 
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Study Findings 
Arena et al. (2004) i. V
.
E/V
.
CO2 slope was a significant predictor of cardiac 
related events. 
 
ii.When V
.
E/V
.
CO2 slope of >34 was combined with  
V
.
O2peak <14ml/kg/min, the V
.
O2peak added prognostic 
power of V
.
E/V
.
CO2 slope to predict hospitalizations but 
not cardiac related mortality. 
 
iii. V
.
E/V
.
CO2 slope was a significantly better predictor of 
cardiac related mortality than V
.
O2peak and was also a 
better predictor of hospitalizations, although the difference 
was not statistically significant in the latter case. 
Table 3- Prognostic Value of High V
.
E/V
.
CO2 Slope Combined with Low V
.
O2peak in CHF  
 
 
Thus, high V
.
E/V
.
CO2 slope (>34) was associated with a higher risk of mortality 
when RERpeak >1.10 was attained. However, this study did not indicate whether high  
V
.
E/V
.
CO2 slope holds the same prognostic value as an important and independent 
predictor of mortality when RERpeak attained was <1.10.  
Many previous researchers have demonstrated V
.
E/V
.
CO2 slope as a strong, 
independent predictor of cardiac related events in the CHF population when a cut off 
value of 34 was used. CHF patients with V
.
E/V
.
CO2 slope of >34 are considered to have 
worse prognosis than those with V
.
E/V
.
CO2 slope of <34 (Chua et al., 1997; Gitt et al., 
2002; Guazzi et al., 2003; Arena et al., 2004).  
Guazzi et al. (2003) demonstrated that V
.
E/V
.
CO2 slope had a stronger prognostic 
power than V
.
O2peak in CHF patients. They showed that non-survivors had lower V
.
O2peak 
and steeper V
.
E/V
.
CO2 slope. But this correlation with V
.
O2peak did not remain once  
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V
.
E/V
.
CO2 slope exceeded a value of 34. In 2007, Arena et al. developed a classification 
system for V
.
E/V
.
CO2 slope as class I: <29, class II: 30 to 35.9, class III: 36 to 44.9 and 
class IV: >45 instead of dichotomizing it at a value of 34. They observed that a 
prognostic value of V
.
E/V
.
CO2 slope was maintained throughout the broad spectrum of 
CHF patients. This classification system stratified the risk in CHF population and 
proposed its utilization for clinical decision making. 
Thus many previous researchers have stated the strong prognostic value of 
V
.
E/V
.
CO2 slope in CHF patients, sometimes as a better predictor than V
.
O2peak.  
According to 2006 guidelines for listing cardiac transplant candidates, it is suggested to 
list CHF candidate with sub-maximal CPX testing with RERpeak <1.05 and V
.
E/V
.
CO2 
slope of >35 (Mehra et al., 2006). However, acknowledging that not all CHF patients 
reach RERpeak >1.10 during maximal exercise testing, it is important to investigate the 
survival probability of patients with RERpeak <1.10 with respect to V
.
E/V
.
CO2 slope.  
 In addition to V
.
E/V
.
CO2 slope, it is important to assess the survival probability in 
the RERpeak group over the given V
.
O2peak strata with respect to other physiologic 
variables. The possible predictors include: age (young/old), sex (male/female), BMI 
(non-obese/obese), CHF etiology (ischemic/non-ischemic), beta-blocker use (yes/no), and 
LVEF (low/high). More studies are needed to investigate whether the above stated 
variables assist in identifying the highest risk subgroup in low RERpeak groups.  
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Age: 
Previous literature illustrates that maximal oxygen uptake decreases with age 
(Mitchell et al., 1958) and elderly individuals have low V
.
O2max (Neuberg et al., 1988). 
Cumming et al. (1972) tested men and women between 40-65 years with progressive 
cycle ergometer maximal exercise and observed that mean V
.
O2max decreased slightly 
from age 40 to 55 years and then declined by 15% from 55 to 60 years and by another 
12% from 60 to 65 years.  
Cicoira et al. (2001) tested CHF patients of >70 years and showed that valid 
exercise testing results could be obtained in >50% of the patients. This indicated the 
feasibility of conducting CPX testing in very elderly CHF population. In this study, 
patients reaching RERpeak >1.0 were included and the rest were excluded as submaximal 
tests. However, RERpeak >1.0 does not indicate the maximal effort according to 
traditional guidelines.  
Previous studies demonstrated that age is not a prognostic indicator in CHF 
patients and is not different among survivors and non-survivors (Mancini et al., 1991; 
Chua et al., 1997; Davies et al., 2000). Further studies are needed to examine the effects 
of age on event risk in patients with lower RERpeak.  
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Sex:  
Females have lower V
.
O2max than males (Neuberg et al., 1988). Davies et al. 
(2000) demonstrated that sex does not have prognostic impact in CHF patients. Thus, 
strong evidence is lacking to determine role of sex affecting prognosis in CHF.  
 
BMI: 
Wasserman (1994) explained that in obese subjects the V
.
O2/work rate 
relationship which reflects amount of O2 utilized by exercising subject to perform 
quantity of external work, is shifted upwards but parallel as compared to non-obese 
subjects. The obese subjects require higher V
.
O2 to move body mass during exercise 
testing and hence they reach predicted V
.
O2max at submaximal level and fatigue at lower 
work rates. It is important to determine if BMI predicts survival probability in low 
RERpeak patients.  
 
Etiology of CHF:  
Previous studies tried to investigate whether differences in etiology of CHF 
(ischemic versus non-ischemic) exist among survivors and non-survivors. Chua et al. 
(1997) and Mancini et al. (1991) did not observe any difference in etiology of heart 
failure between survivors and non-survivors among CHF patients.  
On the contrary, Myers et al. (1998) observed that etiology of CHF was a 
significant predictor of death where patients with ischemic cardiomyopathy had greater 
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risk than non-ischemic cardiomyopathy (RR, 1.73 [95% CI, 1.35 to 2.20]). Recently 
Arena et al. (2005) illustrated that CHF patients with ischemic etiology had a worse 1-
year prognosis than non-ischemic patients. They also showed decreased time to cardiac 
related events, which approached statistical significance (p=0.07). This increased risk of 
adverse events can be attributed to alterations in left ventricular size and function as a 
result of ventricular remodeling. 
 
 Beta-blocker Drugs:  
With recent advances in therapeutic treatment of CHF patients, beta-blockers 
have gained importance with their impact on improved prognosis in CHF. When CHF 
patients of V
.
O2peak <10 ml/kg/min with events (death/transplantation) were compared to 
those with no-events, the event group had a significantly lower percentage of beta-
blocker use than survivors (11% versus 41%) (Mezzani et al., 2003). Metra et al. (2000) 
demonstrated that CHF patients treated with beta-blockers improved symptoms and 
submaximal exercise tolerance due to increased LVEF at rest, improved left ventricular 
stroke volume during exercise, and decreased mean pulmonary artery pressure and 
pulmonary capillary wedge pressure. In 2003, Metra et al. conducted a study of CHF 
patients on long term beta-blockers therapy and observed that 22% of patients had 
increases in LVEF of >15% and these patients had an increased cumulative survival rate 
along with an increased in hospitalization-free survival rate.  
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Beta-blockers have been found to improve survival in CHF patients without 
improving V
.
O2peak. Hence, many researchers have stated the traditional criteria of V
.
O2peak 
of <14 ml/kg/min may not be accurate for determining candidacy for heart transplantation 
and more studies were conducted to see the effects of beta-blocker therapy on survival in 
CHF patients in different V
.
O2peak groups. Pohwani et al. (2003) observed that when CHF 
patients with V
.
O2peak of <14 ml/kg/min were stratified according to beta-blocker usage, 1 
and 3-year survival rate was higher in patients treated with beta-blockers than those not 
treated with beta-blockers. Peterson et al. (2003) demonstrated that no beta-blocker 
treatment was an independent predictor of mortality in CHF patients. In CHF patients 
with V
.
O2peak of <14 ml/kg/min, patients on beta-blockers had an RERpeak of 1.13+0.19 
and patients not on beta-blockers had an RERpeak of 1.10+0.10 (Pohwani e al., 2003). In 
another study, RERpeak in CHF patients with beta-blockers was observed as 1.1+0.1 and 
without beta-blockers as 1.2+0.5 (Peterson et al., 2003). Hence, RERpeak remained 
unaffected by status of beta-blocker treatment.  
 
Left Ventricular Ejection Fraction:  
LVEF has been found to be reduced mainly in CHF patients with systolic 
etiology. Many scientists have investigated the impact of LVEF on prognosis. Mancini et 
al. (1991) demonstrated that LVEF was not significantly different in survivors and non-
survivors groups of CHF patients. On the contrary, Chua et al. (1997) observed that non-
survivors had significantly lower LVEF (22.8+14.7 vs. 31.1+14.6) compared to survivors 
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in CHF population. Similarly, Mezzani et al. (2003) also showed significantly lower 
LVEF in non-survivors than survivors (17% + 6% vs. 23% + 8%) in CHF patients with  
V
.
O2peak <10 ml/kg/min and similar results were seen with V
.
O2peak >10 to <14 ml/kg/min 
group. Further research is needed to investigate whether LVEF determines survival 
probability in low RERpeak groups.    
 The proposed study is designed to determine whether or not the survival 
probability for CHF events indeed varies with RERpeak in CHF patients. Also, it will 
examine the effects of other CPX testing derived and physiologic variables on the 
survival probability in low RERpeak group. It will ultimately help to identify the subgroup 
of low RERpeak with lowest survival probability (highest risk) within given V
.
O2peak 
stratum.  It will assist us to use their CPX data to tailor pharmaceutical or surgical 
therapies despite low RERpeak.  
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CHAPTER III 
OUTLINE OF PROCEDURES 
 
 
The methodology of this study is discussed in this section. The criteria for patient 
selection, procedures for data collection and data analysis are described in detail.  
 
Background 
 The impact of RERpeak on the prognostic value of V
.
O2peak in patients with CHF 
has not yet been clearly defined. In addition, the role of CPX testing derived and other 
physiologic variables as potential predictors of heart failure events is not well defined in 
CHF patients with low RERpeak. Therefore, the specific aims of the proposed study are: 
1) after stratifying CHF patients by V
.
O2peak (<14 ml/kg/min vs. >14 ml/kg/min), examine 
the effects of RERpeak (<1.10 vs. >1.10) on the survival probability for major heart failure 
events over a two-year period; 2a) among those with a low RERpeak within each V
.
O2peak 
stratum, perform bivariate survival analyses examining the effects of the following 
independent variables (considered one at a time) on two-year survival probability for 
major heart failure events: V
.
E/V
.
CO2 slope (low/high), age (young/old), sex 
(male/female), BMI (non-obese/obese), LVEF (low/high), CHF etiology (ischemic/non-
ischemic), and beta-blocker use (yes/no) and 2b) based on the bivariate analyses in Aim 
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2a, identify the subgroups with the statistically significant lower survival probabilities 
within the low RERpeak group and compare to the high RERpeak group within the same 
V
.
O2peak stratum.  To accomplish these objectives, data derived from symptom-limited 
CPX testing in CHF patients and the occurrence of major CHF related events was 
analyzed.  
The following working hypotheses were tested: 1) within each V
.
O2peak stratum, 
CHF patients with a low RERpeak will have a higher probability of survival than patients 
with a high RERpeak. This will likely be due to a portion of the low RERpeak patients 
failing to exercise at a maximal effort; 2a) in CHF patients in low RERpeak group for a 
given V
.
O2peak stratum, the following groups of patients will have a lower probability of 
survival: higher V
.
E/V
.
CO2 slope, older age, lower LVEF, ischemic etiology of CHF, and 
beta blocker non-users. There is little previous research comparing the survival 
probability for major heart failure events between male versus female and obese versus 
non-obese patients. Therefore, the analyses of these variables were exploratory in nature 
and no hypotheses concerning them had been generated and 2b) within each V
.
O2peak 
stratum, the subgroups of low RERpeak identified in Aim 2a as having significantly lower 
survival probabilities for CHF events will have similar probabilities of survival as the 
high RERpeak group.  
The experimental approach of the proposed study was to collect CPX testing data 
for CHF patients with systolic dysfunction. The patients were tested earlier and were 
followed up for a maximum of 24 months at four testing sites. The end points for follow 
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up were included as the first occurrence of any of the following three major cardiac 
events: implantation of LVAD, heart transplantation, or death. The patients who did not 
have any event at the end of follow up period were considered as event-free observations.  
The patients were divided into two groups according to their V
.
O2peak: <14 
ml/kg/min, and >14 ml/kg/min. The patients in each V
.
O2peak stratum were then be 
subdivided into low RERpeak (<1.10) and high RERpeak (>1.10) groups. The survival 
probability and the magnitude of association (relative risk) was calculated and compared 
between these subgroups. The rationale for this approach was that V
.
O2peak is considered 
to be the major criterion for risk stratification and determination of heart transplantation 
candidacy. In order to assess the impact on V
.
O2peak as a function of maximal effort, 
RERpeak is used as a simple and objective criterion. High RERpeak of >1.10 is considered 
as the maximal effort index and tests with low RERpeak of <1.10 are considered 
submaximal. Hence, V
.
O2peak obtained in the latter case can not be used as a reliable 
prognostic indicator. However, not all CHF patients can reach high RERpeak (Aitken et 
al., 1988; Sidney et al., 1977). Although strong evidence is lacking, some physiologic 
factors may contribute to inability to reach high RERpeak such as age related reduction in 
active skeletal mass, decrease in Type II muscle fibers (Anainsson et al., 1981), lesser 
amount of glycogen reserve per unit muscle mass and gradual diffusion of lactic acid 
metabolites from the active tissue into the blood stream (Shephard et al., 1975). 
Furthermore, it is not yet clear to what extent RERpeak defines maximal effort in CHF 
patients (Mezzani et al., 2003).  
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In addition, patients in low RERpeak group within each V
.
O2peak stratum were 
categorized into those with low V
.
E/V
.
CO2 slope (<34) and high V
.
E/V
.
CO2 slope (>34) 
(Chua et al., 1997).  The reason for stratifying by V
.
E/V
.
CO2 slope variable was that it has 
been identified as an independent and strong predictor of prognosis in the CHF 
population (Chua et al., 1997; Corra et al., 2002). The survival probability and magnitude 
of association was then be analyzed and compared between these two groups. Similarly, 
the low RERpeak group within each V
.
O2peak stratum was dichotomized and tested for other 
variables (age, sex, BMI, LVEF, CHF etiology, beta-blocker use) to examine if they 
predict low survival probability for major heart failure events. The rationale for this 
approach was that many CHF patients fail to achieve standard high RERpeak. It is 
important to investigate whether these CPX and physiologic variables help to predict the 
probability of survival in low RERpeak patients. Ultimately, the proposed study was to 
facilitate identification of a subgroup of patients with low RERpeak with lowest survival 
probability (highest risk) that will be comparable to high RERpeak group for a given  
V
.
O2peak stratum. Such findings are important as they will assist the clinicians, to consider 
V
.
O2peak obtained from CPX tests even with low RERpeak, to predict events in CHF 
patients. 
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Research Participants:  
This retrospective research project included a multicenter analysis of CHF 
patients who had undergone exercise testing and subsequent observation at the following 
sites: LeBauer Cardiovascular Research Foundation, Greensboro, NC; Virginia 
Commonwealth University, Richmond, Va; San Paolo Hospital, Milan, Italy; and the VA 
Palo Alto Health Care System and Stanford University, Palo Alto, Calif. Reasons for 
CPX testing included standard CHF assessment, testing for research projects, and 
assessment for implantation of pacemaker devices, LVAD or heart transplantation. The 
severity of CHF varied from moderate to severe and represented the general CHF 
population. The reasons for testing, modes of exercise, exercise testing protocols, and 
computerized metabolic systems measuring ventilatory expired gas analysis were 
different across the centers. However, other standards (equipment calibration before each 
test, monitoring of the patients) and data collection methods were consistent across the 
sites.  
The diagnosis of CHF was based upon physicians‘ diagnoses documented in 
medical records. The main inclusion criteria were: 1) moderate to severe left ventricular 
systolic dysfunction identified as <40 % LVEF (Mezzani et al., 2003; Arena et al., 2007) 
(as obtained from the echocardiography or cardiac catheterization reports that were 
closets to the date of CPX testing); 2) termination of the exercise test according to 
standard ACSM criteria (American College of Sports Medicine, 2006); 3) patients who 
maintained >88 % of oxygen saturation (SaO2 %) during last stage of CPX testing; 4) 
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patients who attained FEV1 >1 L during resting spirometry. These criteria avoided 
inclusion of patients in whom functional impairment was primarily due to pulmonary 
causes rather than cardiovascular causes. Information of patients meeting all of the above 
criteria was obtained from medical records. The exclusion criteria included: 1) patients 
who were on home oxygen therapy; 2) patients with documented history of primary 
obstructive or restrictive pulmonary diseases; 3) premature termination of CPX due to 
abnormal signs, symptoms, ECG responses or technical problems.  
 
Data Collection:  
For the included CHF patients, demographic variables, medication history, and 
exercise variables from CPX testing were obtained from medical records. Demographic 
records were obtained for the following variables: date of CPX test, age, sex, race, BMI, 
LVEF and CHF etiology. For each patient, age was calculated from the date of birth to 
the date of CPX testing. BMI on the day of CPX testing was calculated by using the ratio 
of weight (kg)/ height (m
2
). As stated earlier, LVEF was obtained from the 
echocardiography or cardiac catheterization reports closest to the date of CPX testing. 
The etiology of CHF was divided into two subgroups as ischemic and non-ischemic. 
Ischemic cardiomyopathy included patients with history of coronary artery disease or 
myocardial infarction leading to CHF. Non-ischemic cardiomyopathy included patients in 
whom CHF resulted from idiopathic, alcoholism, drug toxicity, postpartum or 
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peripartum, viral or infiltrative disorders, restrictive and valvular causes. Medication 
history at the time of CPX testing was obtained for intake of beta-blockers.  
Exercise variables were obtained from CPX testing data. It has been demonstrated 
that mode of exercise testing does not impact prognostic characteristics of V
.
O2peak and  
V
.
E/V
.
CO2 slope values derived from CPX testing in heart failure patients (Arena et al., 
2005). Hence, we included patients who had performed treadmill or bike CPX tests 
without creating subgroups. In case of patients who had more than one CPX test, the first 
CPX test data was included in the study in order to avoid the re-entry of the same patient. 
CPX testing data of respiratory gas measurements generated from a breath-by-breath 
analysis by computerized metabolic carts was obtained. It was averaged over 10 or 15-
second intervals. The following CPX testing variables were obtained: V
.
O2peak, RERpeak, 
and V
.
E/V
.
CO2 slope. The V
.
O2peak was expressed as ml/kg/min. It was obtained as the 
highest 30-second average value of V
.
O2 obtained during the last stage of the exercise 
test. The RERpeak was noted as the highest RER observed during the last minute of the 
test. The V
.
E/V
.
CO2 slope was calculated by taking obtained V
.
E (L/min) and V
.
CO2 
(L/min) values from the beginning to the end of exercise session. These values were 
averaged over 10 or 15-second intervals and entered into Microsoft Excel. The V
.
E/V
.
CO2 
slope was calculated using the least squares linear regression equation, y=mx+b where 
m=slope.  
After collecting required data, all the patients were followed up for up to 24 
months starting from the date of CPX testing to record the first occurrence of any of the 
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following end points: implantation of LVAD, heart transplantation, or death. For those 
who had any of these events within 24 months, the follow up time was recorded since the 
date of CPX testing till the date of an event. If no event occurred within 24 months, those 
cases were considered as event-free observations. Following was the rationale for 
choosing a follow up time of 24 months. Davies et al. (2000) followed up elderly CHF 
patients since their CPX testing and observed that they had high mortality within two 
years (Davies et al., 2000) of follow-up. Additionally, Arena et al (2005) demonstrated 
that, the prognostic impact of CPX testing derived variables was time sensitive. The 
specificity of these variables markedly decreased (~20%) as the time past CPX testing 
increased. The longer follow-up periods may also lead to more lost to follow-up cases as 
the patients may change their locations, physicians and visiting hospitals. This would 
particularly have an affect, as this study depends upon hospital records for follow-up 
information. Any patients, who had no medical records available up to 24 months after 
the CPX date, were considered as lost to follow-up.  
It was speculated that some CHF patients would die out of the hospital and in 
those cases; deaths were recorded from the social security death index. In the latter cases, 
it was not possible to trace the cause of death. Hence, the proposed study considered all-
cause mortality rather than just cardiac-related mortality.  
 
 
 
 49 
Data Analysis:  
For Specific Aim 1:  
Since V
.
O2peak is used as a major criterion to determine candidacy for heart transplantation 
in CHF population (Mancini et al., 1991), the proposed study‘s subjects were stratified 
into two groups according to their V
.
O2peak obtained during CPX testing: <14 ml/kg/min 
and >14 ml/kg/min. Relevant studies have demonstrated that patients with V
.
O2peak <14 
ml/kg/min have severe functional intolerance and significantly higher risks of morbidity 
and mortality (Mancini et al., 1991; Chua et al., 1997; Osada et al., 1998; Gitt et al., 
2002; Mezzani et al., 2003). 
 All patients were followed for up to 24 months to identify the date of their first 
major heart failure-related event (LVAD implantation, heart transplantation, or 
mortality). At the end of 24 months, if they had not had any event, those cases were 
considered as event-free observations. Those patients whose event status could not be 
traced prior to conclusion of the study were considered as losses to follow-up and were 
thus treated as censored observations. Inherently, the Kaplan-Meier curve accounts for 
such losses to follow-up as part of its analytical methodology. By constructing a Kaplan-
Meier survival curve, the individuals at risk at any given point represented those 
individuals who were event-free and who had been followed up to at least that point in 
the survival curve. This allowed an accurate estimation of survival probabilities at 
various time points accounting for both events and censored data. 
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The patients in each V
.
O2peak stratum were subdivided according to their RERpeak 
levels (low RERpeak: <1.10;  high RERpeak: >1.10) (Figure 1). The rationale for this 
stratification was that CPX testing with a RERpeak >1.10 has been traditionally considered 
as a ―maximal‖ test and a test with RERpeak <1.10 has been considered as ―submaximal". 
However, research has shown that not all patients can reach high RERpeak (Aitken et al., 
1988; Sidney et al., 1977). Since many patients with CHF cannot attain a high RERpeak, it 
needed to be determined whether a low V
.
O2peak could still predict heart failure events in 
these patients.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51 
V
.
O2peak 
 
 
 
 
V
.
O2peak < 14 ml/kg/min                                                                   V
.
O2peak >14 ml/kg/min 
 
 
 
Low RERpeak  High RERpeak                                                                              Low RERpeak   High RERpeak 
(<1.10)              (> 1.10)                                                               (<1.10)                 (>1.10) 
 
 
Compare the survival probability                                     Compare the survival probability 
and magnitude of association                                            and magnitude of association 
of CHF events                                                                   of CHF events                         
                                                               
Figure 1- Schematic for RERpeak Groups 
                                                                                                                                                      
 
Analysis for Specific Aim 1:  
Within given V
.
O2peak strata, the survival probability in patients with low versus 
high RERpeak was estimated using Kaplan-Meier bivariate survival analyses. Also, the 
magnitude of association for these two groups was computed using simple relative risk 
analyses and compared. A p-value of <0.05 was considered statistically significant.  
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For Specific Aim 2a:  
Within each V
.
O2peak stratum, patients with low RERpeak group were further 
subdivided into two subgroups: low V
.
E/V
.
CO2 slope (<34) and high V
.
E/V
.
CO2 slope 
(>34) (Chua et al., 1997). Rationale for this approach was that previous researchers have 
found a high V
.
E/V
.
CO2 slope to be an effort-independent predictor of morbidity and 
mortality in CHF patients (Chua et al., 1997; Corra et al., 2002). However, its ability to 
predict heart failure events in patients with low RERpeak has not been determined. Hence, 
the proposed study was designed to determine if V
.
E/V
.
CO2 slope holds its significant 
predictive value in low RERpeak groups. The survival probability for low and high  
V
.
E/V
.
CO2 slope was analyzed within the low RERpeak groups of each V
.
O2peak stratum.  
  Similar to analysis of V
.
E/V
.
CO2 slope, additional variables were examined to 
determine if they had predictive value for heart failure events in low RERpeak groups 
within given V
.
O2peak strata. These variables included: age, sex, BMI, LVEF, CHF 
etiology, and beta-blocker use. Each of these variables was dichotomized in the analyses 
as shown in Table 4. 
 
Variables Stratification 
V
.
E/V
.
CO2 slope < 34 > 34 
Sex Male Female 
CHF etiology Ischemic Non-Ischemic 
LVEF (%) < 25% > 25 to 40 % 
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Beta-blockers Usage at the time of CPX test Non-usage at the time of CPX test 
ttesttetestingtesting 
 
 
 
Age (years) < 55  > 55 
BMI (kg/m
2
) < 30 > 30 
Table 4- Stratification of Variables 
 
The roles of all these variables as predictors of heart failure events were determined for 
low RERpeak groups within given V
.
O2peak strata as shown in Figure 2. Specifically, this 
study sought to discover which of these variables identified low survival probability (high 
risk) subgroups (in low RERpeak groups within the V
.
O2peak strata). 
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V
.
O2peak 
 
 
 
 
V
.
O2peak < 14 ml/kg/min                                                                V
.
O2peak >14 ml/kg/min 
 
 
 
Low RERpeak  High RERpeak                                                                                Low RERpeak  High RERpeak 
(<1.10)              (> 1.10)                                                                  (<1.10)            (>1.10)                                                                                                         
 
 
- V
.
E/V
.
CO2 slope                                                               - V
.
E/V
.
CO2 slope                                          
- Age                                                                                  - Age                                        
- Sex                                                                                   - Sex 
- BMI                                                                                 - BMI 
- LVEF                                                                               - LVEF          
- CHF etiology                                                                   - CHF etiology 
- Beta-blocker usage                                                          - Beta-blocker usage 
                                                                                                                                        
Figure 2- Schematic for Stratification of Variables in Low RERpeak Groups 
 
Analysis of Specific Aim 2a:  
The significant predictors of heart failure events for low RERpeak groups within  
V
.
O2peak strata were identified from the list of other CPX testing variables 
(V
.
E/V
.
CO2 slope, age, sex, BMI, LVEF, CHF etiology and beta-blocker usage) using 
bivariate survival analyses. The survival probability for CHF events was calculated using 
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the Kaplan-Meier survival curve method. The difference between the survival 
probabilities was calculated using the Log-rank method. Also, the magnitude of 
associations for these groups was computed using relative risk analyses. The survival 
probabilities and the magnitudes of association were compared between the two 
subgroups of each variable to identify the better predictor of events in the low RERpeak 
groups within a given V
.
O2peak stratum. A p-value of <0.05 was considered statistically 
significant.  
For Specific Aim 2b:  
 Finally, based on the bivariate analysis of each variable described in Aim 2a, this 
study identified the subgroups with statistically significantly lower survival probabilities 
(higher risk) within the low RERpeak group for a given V
.
O2peak stratum. Patients within 
the higher-risk subgroup of a given variable were then compared to the high RERpeak 
group in the same V
.
O2peak stratum for survival probability of events. 
Analysis of Specific Aim 2b: 
The survival probabilities for the best predictors of CHF events in low RERpeak 
group were compared to high RERpeak group within given strata. This was analyzed by 
using Kaplan-Meier survival curve method. A p-value of <0.05 was considered 
statistically significant.  
In conclusion, the ultimate goal was to identify a subgroup of CHF patients with 
low RERpeak (based upon above mentioned variables), who would have comparable 
survival probability as to high RERpeak patients for a given V
.
O2peak strata.           
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Exploratory Analysis:  
 A multivariate proportional hazard analysis (multivariate analysis) was conducted 
in low RERpeak group within low V
.
O2peak stratum. This helped in identifying the 
significantly independent predictors of CHF related events in patients with low RERpeak 
within low V
.
O2peak group.
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CHAPTER IV 
RESULTS 
 
 
Baseline Patient Characteristics 
Table 5 demonstrates the patient characteristics for the low and high V
.
O2peak 
groups, which are divided further into low RERpeak and high RERpeak groups.  The 
continuous variables (RERpeak, age, LVEF, BMI and V
.
E/ V
.
CO2 slope) are presented as 
mean + standard deviation. The nominal variables [sex (males/females), HF etiology 
(ICM/ NICM), and beta-blocker usage (users/ non-users) are expressed as the numbers of 
patients and their percentages for each group.  
 
 
 Overall 
Low VO2pk 
 
(n=367) 
Low VO2pk 
Low RER 
 
(n=207) 
Low VO2pk 
High RER 
 
(n=160) 
Overall 
HighVO2pk 
 
(n=410) 
High VO2pk 
Low RER 
 
(n=194) 
High VO2pk 
High RER 
 
(n=216) 
 
RER peak  
 
 
1.07 + 0.16 
 
0.98 + 0.12 
 
1.20 + 0.10 
 
1.11 + 0.13 
 
1.01 + 0.07 
 
1.20 + 0.1 
 
Age ( years) 
 
54.33 + 13.46 
 
55 + 13.81 
 
 
53 + 12.94 
 
53 + 14.63 
 
53.27+ 15.13 
 
53 + 14.18 
 
Sex(male/female) 
 
% (male/ female) 
 
244/123 
 
66.5 / 33.5 
 
136/ 71 
 
65.7 / 34.3 
 
 
108 / 52 
 
67.5 /  32.5 
 
 339 / 71 
 
82.7 / 17.3 
 
 
 163 / 31 
 
84 / 16 
 
176 / 40 
 
81.5 / 18.5 
 
LVEF (%)  
 
22.27+ 8.01 
 
23.2 + 8.22 
 
 
21.1 + 7.61 
 
26 + 8.61 
 
25.4 + 8.75 
 
26.5 + 8.46 
HF etiology 
 
#  ICM / NICM 
 
% (ICM / NICM) 
 
 
161 / 205 
 
43.9 / 56 
 
 
94 / 112 
 
45.6 / 54.4 
 
 
 
67 / 92 
 
42.1 / 57.9 
 
 
162 / 242 
 
40.1 /  59.9  
 
 
73 / 121 
 
37.6 / 62.4 
 
 
89 / 127 
 
41.2 / 58.8 
 
BMI 
 
29.89 + 7.04  
 
 
29.9 + 6.75 
 
 
29.9 + 7.42 
 
28.4 + 5.79 
 
29.4 + 6.35 
 
27.5 + 5.07 
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Table 5 is continued:  
 
 
Overall 
Low VO2pk 
 
(n=367) 
Low VO2pk 
Low RER 
 
(n=207) 
Low VO2pk 
High RER 
 
(n=160) 
Overall 
HighVO2pk 
 
(n=410) 
High VO2pk 
Low RER 
 
(n=194) 
High VO2pk 
High RER 
 
(n=216) 
VE/VCO2 Slope        41 + 12.19 40 + 11.36 43 + 13.11 32 + 6.88 32 + 8.23 31 + 7.21 
 
BB  
#(Users/ Non-Users) 
 
%(Users/Non-users) 
 
 
( 291 / 76) 
 
(79.3 / 20.7) 
  
 
( 169 / 38 )  
 
(81.6 / 18.4) 
 
 
( 122 / 38 ) 
 
(76.3 / 23.8) 
 
 
(  325 / 85 ) 
 
(79.3 / 20.7) 
 
 
( 155 / 39 ) 
 
( 79.9 / 20.1)  
 
 
( 170 / 46 ) 
 
(78.7 / 21.3) 
Table 5- Baseline Patient Characteristics 
 
The events for each group and subgroup, described as the total number, the percentage, 
and the event-type, are shown in Table 6. 
 
 Overall Low 
VO2peak 
 
Low VO2pk 
Low RER 
Low VO2pk  
High RER 
Overall High 
VO2peak 
High VO2pk 
Low RER 
High VO2pk 
High RER 
Total Events 104 (77%) 
 
  51 (49%) 53 (51%) 31 (23%) 16 (51.6%) 15 (48.4) 
LVADS 11 
 
   7 (63.6%) 4 (36.4%) 5 3 (60%) 2 (40%) 
TRANSPLANTS 39 
 
 14 (35.9%) 25 (64.1%) 10 3 (30%) 7 (70%) 
DEATHS 54   30 (55.6%) 24 (44.4%) 16 10 (62.5%) 6 (37.5%) 
Table 6- CHF Events Distribution According to Groups 
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Earlier studies have demonstrated that patients with V
.
O2peak <14 ml/kg/min are at 
increased risk for events (lower survival) when compared to those with V
.
O2peak >14 
ml/kg/min (Mancini et al., 1991; Roul et al., 1994; Osada et al., 1998; Mezzani et al., 
2003). Hence, the two-year event-free survival probabilities between patients with low  
V
.
O2peak and high V
.
O2peak were compared as shown in Fig. 3.   
 
 
Figure 3- Two-Year Survival Comparison between Low (<14 ml/kg/min) and High (>14 
ml/kg/min) V
.
O2peak 
Legend:  i) Each dip in the Kaplan-Meier curve indicates an event.  
ii) Each vertical line on the curve indicates drop-outs up to that time 
    without an event. 
 60 
Analysis: In this study, the word ‗survival‘ is referred to being free of CHF-related events 
over the two years of follow-up. The log-rank test is used to analyze if the difference in 
event-free survival between the compared groups is significant. The two-year survival 
probability of CHF patients with a low V
.
O2peak (64.2 %) is significantly lower than that 
of CHF patients with a high V
.
O2peak (89.6 %) (Log rank= 60.1, p<0.0001).  
The relative risk of events for V
.
O2peak <14 ml/kg/min versus V
.
O2peak >14 ml/kg/min was 
calculated as follows:          
             Events in low V
.
O2peak group / Total number of patients in V
.
O2peak group  
RR =  ──────────────────────────────────────────────   
             Events in high V
.
O2peak group / Total number of patients in high V
.
O2peak group 
 
             104 / 366  
RR =  ──────  =  3.74 (95 % CI = 2.591 – 5.447) (p< 0.0001)  
             31 / 408 
 
The results for all specific aims and hypotheses will be presented first for the low V
.
O2peak 
group and then for high V
.
O2peak group.  
 
Low V
.
O2peak Analyses:  
Specific Aim 1: After stratifying CHF patients by V
.
O2peak (<14 ml/kg/min vs. >14 
ml/kg/min), examine the effects of RERpeak (<1.10 vs. >1.10) on the survival probability 
for major heart failure events over a two-year period.  
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Figure 4- Two-Year Survival Comparison between Low RERpeak (<1.1) and High 
RERpeak (>1.1) 
 
Analysis: The two-year survival probability for CHF related events is slightly, but 
significantly, higher in the low RERpeak group (68.4 %) as compared to the high RERpeak 
group (58.8 %). (Log rank = 4.1, p= 0.04).  
The relative risk (RR) of events for low RERpeak compared to high RERpeak was 
calculated as follows:  
 
             Events in low RER group / Total number of patients in low RER group  
RR =  ──────────────────────────────────────────   
             Events in high RER group / Total number of patients in high RER group 
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             51 / 206  
RR =  ──────  =  0.747 (95 % CI = 0.541 – 1.034) (p= 0.08)  
             53 / 160 
 
Working Hypothesis 1: Within each V
.
O2peak stratum, CHF patients with a low RERpeak 
will have a higher probability of survival than patients with a high RERpeak. This will 
likely be due to a portion of the low RERpeak patients failing to exercise at a maximal 
effort.  
Conclusion: Based on statistical significance found with the Kaplan-Meier analysis, the 
working hypothesis for Aim 1 is not rejected for the low V
.
O2peak stratum. However, the 
relative risk is not statistically significant. 
 
Specific aim 2a:  
Specific Aim 2a: Among those with a low RERpeak within each V
.
O2peak stratum, perform 
bivariate survival analyses examining the effects of the following independent variables 
(considered one at a time) on two-year survival probability for major heart failure events: 
V
.
E/ V
.
CO2 slope (low/high), age (young/old), sex (male/female), BMI (non-obese/obese), 
LVEF (low/high), CHF etiology (ischemic/non-ischemic), and beta-blocker use (yes/no). 
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1) Comparing Survival Probability for Low (<34) versus High (>34) V
.
E/ V
.
CO2 Slope in 
Patients with V
.
O2peak <14ml/kg/min and RERpeak <1.10: 
 
 
Figure 5- Two-Year Survival Comparison between Low (<34) and High (>34) V
.
E/ V
.
CO2 
Slope 
 
Analysis: The two-year survival probability of CHF patients with high V
.
E/ V
.
CO2 slope 
is significantly lower (63.6%) than those with low V
.
E/ V
.
CO2 slope (82.3%) (Log rank= 
6.3, p= 0.01).   
The relative risk of events for high V
.
E/ V
.
CO2 slope compared to low V
.
E/ V
.
CO2 slope 
was calculated as follows:  
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             Events in high slope group / Total number of patients in high slope group  
RR =  ──────────────────────────────────────────   
             Events in low slope group / Total number of patients in low slope group 
 
             42 / 146  
RR =  ──────  =  2.219 (95 % CI = 1.116 – 4.678) (p= 0.026)  
             7 / 54 
 
2) Comparing Survival Probability for Low (<25 %) versus High (>25 %) LVEF in 
Patients with V
.
O2peak <14ml/kg/min and RERpeak <1.10: 
 
 
Figure 6- Two-Year Survival Comparison between Low (<25%) and High (>25) LVEF 
Analysis: The two-year survival probability of CHF patients with low LVEF is 
significantly lower (59.3 %) than those with high LVEF (78.8 %) (Log rank= 7, p= 
0.008).  
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The relative risk of events for low LVEF versus high LVEF was calculated as follows:  
              
             Events in low LVEF group / Total number of patients in low LVEF group  
RR =  ────────────────────────────────────────────   
             Events in high LVEF group / Total number of patients in high LVEF group 
 
             35 / 109  
RR =  ──────  =  1.947 (95 % CI = 1.171 – 3.303) (p= 0.01)  
             16 / 97 
 
3) Comparing Survival Probability for Ischemic versus Non-Ischemic etiology of CHF in 
Patients with V
.
O2peak <14ml/kg/min and RERpeak <1.10: 
 
 
Figure 7- Two-Year Survival Comparison between Ischemic and Non-Ischemic Etiology 
of CHF 
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Analysis: The two-year survival probability of CHF patients with ischemic etiology is 
significantly lower (58.4 %) than those with non-ischemic etiology (76.6 %) of HF (Log 
rank= 4.5, p= 0.03).  
The relative risk of events for ischemic versus non-ischemic etiology of CHF was 
calculated as follows:  
 
             Events in ischemic group / Total number of patients in ischemic group  
RR =  ──────────────────────────────────────────────   
             Events in non-ischemic group / Total number of patients in non-ischemic group 
 
             30 / 94  
RR =  ──────  =  1.687 (95 % CI = 1.045 – 2.740) (p= 0.036)  
             21 / 111 
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4) Comparing Survival Probability for Beta-blocker Users versus Beta-blocker Non- 
Users in Patients with V
.
O2peak <14ml/kg/min and RERpeak <1.10: 
 
 
 
Figure 8- Two-Year Survival Comparison between Beta-blocker Users and Non-Users  
 
Analysis: The two-year survival probability of beta-blocker non-users is significantly 
lower (43.3 %) than those of beta-blocker users (74.7 %) (Log rank= 20.9, p= <0.001).  
The relative risk of events for beta-blocker non-users versus users was calculated as 
follows:  
 
             Events in beta-blocker non-users / Total number of beta-blocker non-users  
RR =  ──────────────────────────────────────────── 
             Events in beta-blocker users / Total number of beta-blocker users 
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             20 / 38  
RR =  ──────  =  2.852 (95 % CI = 1.819 – 4.209) (p < 0.001)  
             31 / 168 
 
 
5) Comparing Survival Probability for young (<55) versus old age (>55) groups in 
Patients with V
.
O2peak <14ml/kg/min and RERpeak <1.10: 
 
 
Figure 9- Two-Year Survival Comparison between Young Age (<55) and Old Age (>55)  
 
Analysis: The two-year survival probability of old age group (67.3 %) is not different 
than young age group (69.4 %) (Log rank= 0, p= 0.898).  
The relative risk of events for old versus young age group was calculated as follows: 
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             Events in old age group / Total number of patients in old age group  
RR =  ──────────────────────────────────────────── 
             Events in young age group / Total number of patients in young age group 
 
             27 / 108  
RR =  ──────  =  1.021 (95 % CI = 0.636 – 1.645) (p >0.99)  
             24 / 98 
 
 
6) Comparing Survival Probability for Males versus Females in Patients with V
.
O2peak 
<14ml/kg/min and RERpeak <1.10: 
 
 
Figure 10- Two-Year Survival Comparison between Males and Females  
 
Analysis: The two-year survival probability is not different between males (64.4%) and 
females (75.1%) groups of CHF patients. (Log rank= 0.8, p= 0.362). 
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The relative risk of events for males versus females was calculated as follows: 
 
             Events in male group / Total number of males  
RR =  ────────────────────────────── 
             Events in female group / Total number of females              
            
             36 / 136  
RR =  ──────  =  1.235 (95 % CI = 0.742 – 2.118) (p= 0.497)  
             15 / 70 
 
 
7) Comparing Survival Probability for Low (<30 kg/m
2
) versus High (>30 kg/m
2
) BMI in 
Patients with V
.
O2peak <14ml/kg/min and RERpeak <1.10: 
 
 
Figure 11- Two-Year Survival Comparison between Low BMI (<30) and High BMI 
(>30)  
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Analysis: The two-year survival probability is not different between low BMI group 
(64.4 %) and high BMI group (72.2 %) (Log rank= 1.3, p=0.256).  
The relative risk of events for low BMI versus high BMI was calculated as follows: 
 
            
             Events in low BMI group / Total number of patients in low BMI group 
RR =  ────────────────────────────────────────── 
             Events in high BMI group / Total number of patients in high BMI group 
              
             30 / 113  
RR =  ──────  =  1.176 (95 % CI = 0.729 – 1.917) (p= 0.522)  
             21 / 93 
 
Working Hypothesis 2a:  In CHF patients in low RERpeak group for a given V
.
O2peak 
stratum, the following groups of patients will have a lower probability of survival: higher 
V
.
E/ V
.
CO2 slope, older age, lower LVEF, ischemic etiology of CHF, and beta blocker 
non-users. There is little previous research comparing the survival probability for major 
heart failure events between male versus female and obese versus non-obese patients. 
Therefore, the analyses of these variables are exploratory in nature and no hypotheses 
concerning them have been generated.  
Conclusion: According to the results observed from items 1-7 for specific Aim 2a, the 
groups of high V
.
E/ V
.
CO2 slope (>34), low LVEF (<25 %), ischemic etiology of CHF, 
and beta-blocker non-users had significantly lower survival probabilities. The results of 
these four variables are summarized in following Table 7.  
Hence, the working hypothesis for Aim 2a is not rejected for high V
.
E/ V
.
CO2 
slope (>34), low LVEF (<25 %), ischemic etiology of CHF, and beta-blocker non-use 
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variables in the low V
.
O2peak stratum. However, the working hypothesis for Aim 2a in the 
low V
.
O2peak stratum is rejected for age. 
In addition, exploratory analyses for sex and BMI variables revealed that the two-
year survival probabilities for males versus females and for low BMI versus high BMI 
groups are not different in CHF patients with V
.
O2peak <14 ml/kg/min and RERpeak <1.10.  
 
 
 
Finding  Log rank and Significance Relative risk and 95% CI 
1) Beta-blocker (BB) Non-
users have lower 2-year 
survival probability than beta-
blocker users 
Log rank= 20.9 
 
p <0.001 
Relative risk of event for BB 
non-users compared to users 
=2.852  
(95% CI = 1.819 – 4.209)  
(p <0.001) 
 
2) High VE/VCO2 slope group 
has lower 2-year survival 
probability than low VE/VCO2 
slope 
 
Log rank= 6.3 
 
p= 0.01 
Relative risk of event for high 
slope compared to low slope  
=2.219  
(95 % CI = 1.116 – 4.678)  
(p= 0.026) 
 
3) Low LVEF group has lower 
2-year survival probability 
than high LVEF 
 
Log rank= 7 
 
p= 0.01 
Relative risk of event for low 
LVEF compared to high 
LVEF  
=1.947  
(95 % CI = 1.171 – 3.303)  
(p= 0.01) 
 
4) Ischemic etiology group has 
lower 2-year survival 
probability than non-ischemic 
etiology 
 
Log rank= 4.5  
 
p= 0.03 
Relative risk of event for 
ischemic etiology compared to 
non-ischemic etiology  
=1.687  
(95 % CI = 1.045 – 2.740)  
(p= 0.03)  
 
Table 7- Significant Variables in Aim 2a for CHF Patients with V
.
O2peak <14 ml/kg/min 
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Specific aim 2b:  
Specific aim 2b: Based on the bivariate analyses in aim 2a, identify the subgroups with 
the statistically significant lower survival probabilities within low RERpeak group and 
compare to the high RERpeak group within the same V
.
O2peak stratum.  
 
1) Comparing Survival Probability for Non Beta-blocker Users in Low RERpeak group 
versus the High RERpeak group within V
.
O2peak <14 ml/kg/min stratum: 
 
 
Figure 12- Two-Year Survival Comparison between Beta-Blocker Non-Users in Low 
RERpeak Group versus High RERpeak Group within Low V
.
O2peak Stratum 
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Analysis: The two-year survival probability of CHF patients with low RERpeak and non-
users of beta-blockers is slightly, but not significantly, lower (43.3 %) than the survival 
of patients with high RERpeak (58.8 %) within the low V
.
O2peak stratum (Log rank= 3.7, p= 
0.05).   
The relative risk of events for patients with low RERpeak with non beta-blocker use as 
compared to high RERpeak was calculated as follows:  
 
 
                  Events in low RERpeak-   /   Total number of patients in low RERpeak- 
                  Non BB use group                 Non BB use group  
RR =  ──────────────────────────────────────────   
             Events in high RERpeak group / Number of patients in high RERpeak group 
                                                              
             20 / 38  
RR =  ──────  =  1.589 (95 % CI = 1.064 – 2.207) (p= 0.039)  
             53 / 160 
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2) Comparing Survival Probability for Patients with Low RERpeak-High VE-VCO2 slope 
versus the High RERpeak group within V
.
O2peak <14 ml/kg/min stratum: 
 
 
Figure 13- Two-Year Survival Comparison between High VE-VCO2 Slope in Low 
RERpeak Group versus High RERpeak Group within Low V
.
O2peak Stratum 
 
Analysis: There is no difference between the two-year survival probability for patients of 
low RERpeak with high V
.
E/ V
.
CO2 slope (63.6 %) and those with high RERpeak (58.8 %) 
within low V
.
O2peak stratum (Log rank= 0.8, p=0.36).  
The relative risk of events for patients of low RERpeak with high V
.
E/ V
.
CO2 slope as 
compared to high RERpeakwas calculated as follows: 
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              Events in low RERpeak-       /     Total number of patients in low RERpeak- 
             high VE/VCO2 slope group         high VE/VCO2 slope group        
RR =  ──────────────────────────────────────────   
             Events in high RERpeak group / Number of patients in high RERpeak group 
                                                                
             42 / 146  
RR =  ──────  =  0.868 (95 % CI = 0.619 – 1.213) (p= 0.459)  
             53 / 160 
 
 
 
3) Comparing Survival Probability for Patients with Low RERpeak -Low LVEF versus the 
High RERpeak group within V
.
O2peak <14 ml/kg/min stratum: 
 
 
Figure 14- Two-Year Survival Comparison between Low LVEF in Low RERpeak  
 Group versus High RERpeak Group within Low V
.
O2peak Stratum.  
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Analysis: The two-year survival probability between patients with low RERpeak with low 
LVEF (59.3 %) is not different from those with the high RERpeak (58.8 %) (Log rank= 
0.2, p=0.695).  
The relative risk of events for patients of low RERpeak with low LVEF as compared to 
high RERpeak was calculated as follows: 
 
             Events in low RERpeak-       /     Total number of patients in low RERpeak- 
             low LVEF group                          low LVEF group        
RR =  ──────────────────────────────────────────   
             Events in high RERpeak group / Number of patients in high RERpeak group 
           
             35 / 109  
RR =  ──────  =  0.969 (95 % CI = 0.679 – 1.368) (p= 0.895)  
             53 / 160 
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4) Comparing Survival Probability for Patients with Low RERpeak -Ischemic Etiology 
versus the High RERpeak group within V
.
O2peak <14 ml/kg/min stratum: 
 
 
Figure 15- Two-Year Survival Comparison between Ischemic Etiology in Low RERpeak 
Group versus High RERpeak Group within Low V
.
O2peak Stratum 
 
 
Analysis: The two-year survival probability between patients of low RERpeak with 
ischemic etiology of HF (58.4 %) and those with the high RERpeak (58.8 %) is not 
different (Log rank= 0.2, p=0.632).  
The relative risk of events for patients of low RERpeak with ischemic etiology of HF as 
compared to high RERpeak was calculated as follows: 
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             Events in low RERpeak-       /     Total number of patients in low RERpeak- 
             ischemic etiology group             ischemic etiology group        
RR =  ──────────────────────────────────────────   
             Events in high RERpeak group / Number of patients in high RERpeak group 
                                                                
 
             30 / 94  
RR =  ──────  =  0.963 (95 % CI = 0.662 – 1.379) (p= 0.89)  
             53 / 160 
 
Working Hypothesis 2b: Within each V
.
O2peak stratum, the subgroups of low RERpeak 
identified in Aim 2a as having significantly lower survival probabilities for CHF events 
will have similar probabilities of survival as the high RERpeak group.  
Conclusion: The two-year survival probabilities of low RERpeak CHF patients without 
beta-blocker use, with high V
.
E/ V
.
CO2 slope, with low LVEF, or with ischemic etiology 
of HF are not significantly different from those of patients with a high RERpeak within the 
low V
.
O2peak stratum.  
Hence, the working hypothesis for Aim 2b is not rejected for the low V
.
O2peak stratum.  
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Exploratory Analyses in Patients with Low RERpeak in Low V
.
O2peak Stratum: 
A multivariate proportional hazard analysis (multivariate analysis) was conducted 
by including the variables V
.
E/ V
.
CO2 slope (<34 or >34), LVEF (<25 or >25), beta-
blocker treatment (user or non-user), etiology of CHF (ischemic or non-ischemic), age 
(<55 or >55), sex (males or females), and BMI (<30 or >30). The significant independent 
predictors of CHF related events were no beta-blocker treatment and low LVEF. This 
analysis showed that, when beta-blocker usage was included in the model,  
V
.
E/ V
.
CO2 slope and HF etiology were no longer significant predictors of CHF events. 
However, HF etiology approached statistical significance (p=0.06).  Age, sex and BMI 
were not significant predictors of CHF-related events. The result of this analysis is shown 
in the Table 8 below.  
 
 
Variable p-value 
Beta-blocker  <0.001 
LVEF 0.004  
Etiology 0.06  
VE/VCO2 slope 0.13  
Table 8- Multivariate Proportional Hazard Analysis Results for Low RERpeak Group 
within V
.
O2peak <14 ml/kg/min when V
.
E/ V
.
CO2 Slope is Entered with Cut-Off at 34 
 
Beta-blocker use confounded the analysis. Out of 38 patients in the low RERpeak 
group who did not receive beta-blocker treatment, 35 (92.1%) had a V
.
E/ V
.
CO2 slope of 
>34 and 19 (54.3%) of these 35 patients had an event.  
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To expand the exploratory analysis further, the V
.
E/ V
.
CO2 slope was divided into four 
ventilatory classes (VC) formerly described by Arena et al. (2007). These four classes 
are- class I: V
.
E/ V
.
CO2 slope of <29, class II: V
.
E/ V
.
CO2 slope of 30-35.9, class III:  
V
.
E/ V
.
CO2 slope of 36-44.9 and class IV: V
.
E/ V
.
CO2 slope of >45. As shown in Table 9, 
the percentage of patients not receiving beta-blocker was higher in classes III and IV than 
in classes I and II.  
 
 
 Ventilatory class N and % of patients 
1)  Class I: VE/VCO2 slope <29:  Total N=20 
                              Beta-blocker Users  N=18 (90%)  
                              Beta-blocker Non-users  N=2   (10%)  
2)  Class II: VE/VCO2 slope 30-35.9: Total N=57 
                               Beta-blocker Users N=54  (94.7%) 
                               Beta-blocker Non-users N=3    (5.3%) 
3)  Class III: VE/VCO2 slope 36-44.9: Total N=79 
                               Beta-blocker Users N=55  (69.6%) 
                               Beta-blocker Non-users N=24  (30.4%) 
4) Class IV: VE/VCO2 slope >45: Total N=44 
                               Beta-blocker Users N=35  (79.5%) 
                               Beta-blocker Non-users N=9    (20.5%) 
 
Table 9- Distribution of Beta-blocker Users and Non-Users across Ventilatory Classes 
 
The two-year survival probabilities of CHF patients are compared across the four 
ventilatory classes within low RERpeak group in low V
.
O2peak stratum as shown in Fig. 16 
below.  
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Comparing Survival Probability using four classes of V
.
E/ V
.
CO2 slope in low RERpeak 
group of low V
.
O2peak stratum <14 ml/kg/min:  
 
 
Figure 16- Two-Year Survival Comparison Across Four Ventilatory Classes of  
V
.
E/ V
.
CO2 Slope in Low RERpeak Group within Low V
.
O2peak Stratum 
 
This analysis shows that as the ventilatory class increases the probability of survival 
significantly decreases in CHF patients with low RERpeak within the low V
.
O2peak group 
(Log rank= 11.5, p= 0.009).  
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Next, multivariate analysis was conducted entering V
.
E/ V
.
CO2 slope into the 
model as the four classes described above. The four variables appeared to be significant 
independent predictors of CHF-related events from this analysis and they are shown 
below in Table 10. In contrast to earlier model with V
.
E/ V
.
CO2 slope cut-point at 34, this 
multivariate proportional hazard model demonstrated that V
.
E/ V
.
CO2 slope maintained 
statistical significance when the beta-blocker variable was included. Additionally, the 
significance of the CHF etiology variable increased (p=0.05 vs. 0.02). As already shown 
in the bivariate analysis, age, sex and BMI variables were not significant predictors of 
CHF-related events in this model.  
 
 
Variable Significance 
beta-blocker <0.001 
VE/VCO2 slope 0.01 
LVEF 0.01 
etiology of CHF 0.02 
Table 10- Multivariate Proportional Hazard Analysis Results for Low RERpeak Group 
within V
.
O2peak <14 ml/kg/min when V
.
E/ V
.
CO2 Slope is Entered as Continuous Variable 
 
 The analysis in Fig. 16 demonstrated that patients with V
.
E/ V
.
CO2 slope >45 (VC 
IV) had the lowest two-year event-free survival. Hence, this cut-off value was used to 
dichotomize the V
.
E/ V
.
CO2 slope data as high V
.
E/ V
.
CO2 slope >45 and low V
.
E/ V
.
CO2 
slope <45 to perform survival analysis as shown in Fig. 17 below.  
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Figure 17- Two-Year Survival Comparison between Low (<45) and High (>45)  
V
.
E/ V
.
CO2 Slope 
 
Analysis: The survival probability of CHF patients with high V
.
E/ V
.
CO2 slope is 
significantly lower (50.9 %) than those with low V
.
E/ V
.
CO2 slope (73.4 %) (Log rank= 
8.4, p= 0.003).   
The relative risk of events for high V
.
E/ V
.
CO2 slope compared to low V
.
E/ V
.
CO2 slope 
was 1.719 (p= 0.04)  (95% CI= 1.030- 2.734).  
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The multivariate analysis was performed entering the V
.
E/ V
.
CO2 slope into the 
model as a dichotomized variable (>45 vs. <45).  Four variables appeared to be 
significant independent predictors of CHF related events in patients with low RERpeak in 
the low V
.
O2peak stratum as demonstrated in Table 11 below. Unlike when 34 was used as 
the cut-point, the V
.
E/ V
.
CO2 slope >45 maintained statistical significance when beta-
blocker variable was added to the model. The variables age, sex and BMI were not 
significant predictors.  
 
 
Variable Significance 
beta-blocker 0.0001 
VE/VCO2 slope 0.003 
LVEF 0.007 
Etiology of CHF 0.01 
Table 11- Multivariate Proportional Hazard Analysis Results for Low RERpeak Group 
within V
.
O2peak <14 ml/kg/min when V
.
E/ V
.
CO2 Slope is Entered with Cut-Off at 45 
 
High V
.
O2peak Analyses:  
Specific Aim 1: 
Specific Aim 1: After stratifying CHF patients by V
.
O2peak (<14 ml/kg/min vs. >14 
ml/kg/min), examine the effects of RERpeak (<1.10 vs. >1.10) on the survival probability 
for major heart failure events over a two-year period. 
The findings for specific Aim 1 for high V
.
O2peak stratum are summarized in Table 12 as 
shown below.  
 86 
 
Finding  Log rank and Significance Relative risk and 95% CI 
 
The low RERpeak group had 
a lower 2-year survival 
(88.6 %) than the high 
RERpeak group (90.5 %). 
The difference is non-
significant.  
 
Log rank= 0.3 
 
p= 0.56 
Relative risk of event for 
low RERpeak compared to 
high RERpeak 
= 1.188  
(95% CI = 0.610 – 2.317)  
(p= 0.71) 
 
Table 12- Survival Analysis for Aim 1 in Patients with Low RERpeak  and High V
.
O2peak  
 
Working Hypothesis 1: Within each V
.
O2peak stratum, CHF patients with a low RERpeak 
will have a higher probability of survival than patients with a high RERpeak. This will 
likely be due to a portion of the low RERpeak patients failing to exercise at a maximal 
effort.  
Conclusion: The survival probabilities between the low RERpeak group and the high 
RERpeak group within the high V
.
O2peak stratum are not different.  Therefore, the working 
hypothesis for Aim 1 is rejected for high V
.
O2peak stratum.  
 
Specific aim 2a:  
Specific Aim 2a: Among those with a low RERpeak within each V
.
O2peak stratum, perform 
bivariate survival analyses examining the effects of the following independent variables 
(considered one at a time) on two-year survival probability for major heart failure events: 
V
.
E/ V
.
CO2 slope (low/high), age (young/old), sex (male/female), BMI (non-obese/obese), 
LVEF (low/high), CHF etiology (ischemic/non-ischemic), and beta-blocker use (yes/no). 
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The Kaplan-Meier bivariate survival analyses are performed for the variables 
described in Aim 2a for high V
.
O2peak stratum. The findings are described in Table 13 as 
shown below.  
 
 
Findings  Log rank and Significance Relative risk and 95% CI 
 
1) The high VE/VCO2 slope 
group had a significantly 
lower 2-year survival 
probability (71.1 %) than 
low VE/VCO2 slope group 
(95.6 %).  
 
Log rank= 16.3 
 
p< 0.001 
Relative risk of event for 
high VE/VCO2 slope as 
compared to low VE/VCO2 
slope 
= 5.1 
(95% CI = 1.817 – 14.716)  
(p= 0.002) 
 
2) The low LVEF group 
had a significantly lower 2-
year survival probability 
(81.8 %) than the high 
LVEF group (93.8 %) 
 
Log rank= 7.1  
 
p= 0.007 
Relative risk of event for 
low LVEF as compared to 
high LVEF  
= 3.655  
(95% CI = 1.297 – 10.570)  
(p= 0.017) 
 
3) The 2-year survival 
probability for males (90 %) 
and females (80.9 %) was 
not significantly different.  
 
Log rank= 1 
 
p= 0.313 
Relative risk of event for 
males as compared to 
females  
= 0.574 
(95% CI = 0.213 – 1.640) 
(p= 0.296) 
 
4) The 2-year survival 
probability for the old age 
group (90.1 %) and the 
young age group (87.4 %) is 
not significantly different. 
 
Log rank= 0.2  
 
p= 0.642 
Relative risk of event for 
old age group as compared 
to young age group  
= 0.779  
(95% CI = 0.301 – 1.984) 
(p= 0.793) 
 
 
Table 13 is continued on next page:  
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Findings  Log rank and Significance Relative risk and 95% CI 
 
5) The 2-year survival 
probability for ischemic 
etiology (85.5 %) and non-
ischemic etiology of HF 
(90.5 %) is not different. 
Log rank= 0.1 
 
p= 0.775 
Relative risk of event for 
ischemic etiology as 
compared to non-ischemic 
etiology  
= 1.268 
(95% CI = 0.504 – 3.163) 
(p= 0.604) 
 
6) The 2-year survival 
probability for low BMI 
(88.8 %) and high BMI 
(88.1 %) is not different.  
 
Log rank= 0 
 
p= 0.889 
Relative risk of event for 
low BMI as compared to 
high BMI 
= 0.846 
(95% CI = 0.340 – 2.109) 
(p= 0.797) 
 
7) The 2-year survival 
probability for beta-blocker 
non-users (87.5 %) and 
beta-blocker users (89.4) is 
not different.  
Log rank= 0  
 
p= 0.98  
Relative risk of event for 
beta-blocker non-users as 
compared to beta-blocker 
users  
= 1.316 
(95% CI = 0.459 – 3.612)  
(p= 0.74) 
 
Table 13- Survival Analyses for Aim 2a in Patients with RERpeak <1.10 and V
.
O2peak >14 
ml/kg/min 
 
Working Hypothesis 2a:  In CHF patients in the low RERpeak group for a given V
.
O2peak 
stratum, the following groups of patients will have a lower probability of survival: higher 
V
.
E/ V
.
CO2 slope, older age, lower LVEF, ischemic etiology of CHF, and beta blocker 
non-users. There is little previous research comparing the survival probability for major 
heart failure events between male versus female and obese versus non-obese patients. 
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Therefore, the analyses of these variables are exploratory in nature and no hypotheses 
concerning them have been generated.  
Conclusion: According to the findings described in Table 13, high V
.
E/ V
.
CO2 slope and 
low LVEF have significantly lower survival probability. The survival analyses performed 
for etiology of CHF and beta-blockers did not show differences in survival. In addition, 
exploratory analyses for sex and BMI variables revealed that the two-year survival 
probabilities for males versus females and for low BMI versus high BMI groups are not 
different in CHF patients with V
.
O2peak >14 ml/kg/min and RERpeak <1.10.  
Hence, the working hypothesis for Aim 2a in high V
.
O2peak stratum is not rejected 
for high V
.
E/ V
.
CO2 slope (>34) and low LVEF (<25 %). However, the working 
hypothesis for Aim 2a in high V
.
O2peak stratum is rejected for etiology of CHF, beta-
blockers and age variables.  
 
Specific aim 2b: 
Specific Aim 2b: Based on the bivariate analyses in Aim 2a, identify the subgroups with 
the statistically significant lower survival probabilities within the low RERpeak group and 
compare to the high RERpeak group within the same V
.
O2peak stratum 
The results obtained for specific Aim 2b are described in Table 14 as shown below.  
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Finding  Log rank and Significance Relative risk and 95% CI 
 
1) The group of Low 
RERpeak-high VE/VCO2 
slope had a significantly 
lower 2-year survival 
probability (72.6 %) than 
high RERpeak group (90.5 
%).  
 
Log rank= 9.2 
 
p= 0.002 
Relative risk of event for 
low RERpeak-high VE/VCO2 
slope as compared to high 
RERpeak group 
=2.324 
(95% CI = 1.148 – 4.662)  
(p= 0.034) 
2) The group of Low 
RERpeak-low LVEF had a 
significantly lower 2-year 
survival probability (81.8%) 
than the high RERpeak group 
(90.5 %). 
Log rank= 4.2  
 
p= 0.04 
Relative risk of event for 
low RERpeak-low LVEF as 
compared to high RERpeak 
group 
=1.977 
(95% CI = 0.972 – 3.990)  
(p= 0.075) 
 
Table 14- Survival Analyses for Aim 2b in Patients with V
.
O2peak >14 ml/kg/min 
 
Working Hypothesis 2b: Within each V
.
O2peak stratum, the subgroups of low RERpeak 
identified in Aim 2a as having significantly lower survival probabilities for CHF events 
will have similar probabilities of survival as the high RERpeak group. 
Conclusion: For the high V
.
O2peak stratum, the low RERpeak groups with high V
.
E/ V
.
CO2 
slope and low LVEF have similar, or even lower, two-year survival probabilities than that 
of the high RERpeak group. Hence, the working hypothesis of aim 2b is not rejected for 
high V
.
O2peak stratum. 
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Summary of Results:  
CHF patients with low V
.
O2peak (<14 ml/kg/min) have significantly lower two-year 
event-free survival as do those with high V
.
O2peak. In the low V
.
O2peak group, patients with 
a high RERpeak (>1.10) have lower event-free two-year survival than those with low 
RERpeak. The bivariate survival analyses in the low RERpeak group within the low V
.
O2peak 
stratum revealed that patients with high V
.
E/ V
.
CO2 slope (>34), low LVEF (<25 %), 
ischemic etiology of CHF, and beta-blocker non-use have significantly lower two-year 
event-free survival rates that are comparable to that of the high RERpeak group within the 
same V
.
O2peak stratum.  
Exploratory multivariate analyses in CHF patients with low RERpeak and low  
V
.
O2peak revealed that beta-blockers, V
.
E/ V
.
CO2 slope, LVEF, and ischemic etiology of 
CHF were significant independent predictors of CHF-related events when V
.
E/ V
.
CO2 
slope was classified into four ventilatory classes.  
 In conclusion, in the low RERpeak (<1.10) group having a V
.
O2peak <14 ml/kg/min, 
CHF patients with no beta-blocker use, V
.
E/ V
.
CO2 slope >45, LVEF <25%, and ischemic 
etiology of CHF are at increased risk of CHF related events (LVAD implantation, heart 
transplantation, death) within the following two years.  
 
 
 
 
 
 
 
 
 
 92 
CHAPTER V 
 
DISCUSSION 
 
 
CPX testing is the gold standard modality used to assess functional capacity and 
to tailor therapeutic and surgical options for the CHF population. Although RERpeak 
>1.10 is accepted as an indicator of maximal effort in CHF patients, it has been observed 
that a significant proportion (~50%) of patients are unable to attain this RER  
(unpublished results, HF Action database, LeBauer Cardiovascular Research 
Foundation). Controversy exists over the predictive value of CPX testing in CHF patients 
with a low RERpeak <1.10 and whether or not significant predictors of CHF related events 
exist in this particular group. Hence, the focus of this study was to determine if specific 
variables derived from CPX testing can be used to predict major heart failure events 
(LVAD implantation, heart transplantation, death) in CHF patients with systolic 
dysfunction when RERpeak is lower than 1.10.  
Earlier studies have demonstrated that patients with a V
.
O2peak <14 ml/kg/min are 
at increased risk of CHF related events. Therefore, this V
.
O2peak value has been used as an 
important selection criterion for heart transplantation candidacy (Mancini et al., 1991; 
Roul et al., 1994). The present analysis also shows that the two-year CHF related event 
free survival probability is significantly lower (64.2%) in patients with V
.
O2peak <14 
ml/kg/min than in patients with V
.
O2peak >14 ml/kg/min (89.6%) (Fig. 3). Previously,
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Osada et al. (1998) observed V
.
O2peak <14 ml/kg/min as an independent predictor of death 
in CHF patients who performed symptom limited CPX testing when the mean RERpeak 
was 1.11+0.2. Roul et al. (1994) found a low V
.
O2peak to be predictive of pulmonary 
edema, hospitalization for HF or severe ventricular arrhythmia, but did not report 
RERpeak. Mancini et al. (1991) observed a lower survival rate in patients with low V
.
O2peak 
who performed ‗maximal‘ CPX testing, but RERpeak was not reported. As the present 
study includes CHF patients with both low and high RERpeak, it extends the prognostic 
value of V
.
O2peak to a wider population of CHF patients. 
According to the criteria for maximal CPX testing, a low RERpeak may indicate a 
submaximal effort. Out of total 774 CHF patients who underwent CPX testing, 367 
(47.4%) patients had a V
.
O2peak <14 ml/kg/min and 408 (52.6%) patients had a V
.
O2peak 
>14 ml/kg/min. In the lower V
.
O2peak group, 207 (56.4%) patients could not attain a 
RERpeak 1.10. When the survival probabilities were compared between patients with a 
RERpeak <1.10 and a RERpeak >1.10, the results showed that the patients with higher 
RERpeak had significantly lower survival than those with lower RERpeak (Fig. 4). This 
finding was present in both the low and high V
.
O2peak groups (Table 12). This result may 
be attributed to the portion of low RERpeak patients failing to exercise at a maximal effort.  
The finding of the present study is similar to that of Mezzani et al. (2003) who employed 
a V
.
O2peak cut-off of 10 ml/kg/min. They demonstrated that patients with V
.
O2peak <10 
ml/kg/min and RERpeak >1.15 had significantly worse survival than patients with V
.
O2peak 
<10 and RERpeak <1.15. Additionally, the latter group‘s survival was similar to that of a 
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higher V
.
O2peak group (10-14 ml/kg/min). Hence, it was suggested that patients should be 
encouraged to exercise until RERpeak approaches 1.15. Arena et al. (2004) also reported 
that patients with a RERpeak <1.10 had a lower percentage (27%) of events (cardiac 
related hospitalizations) as compared to patients with a RERpeak >1.10 (32%).  
 Although a low RERpeak can been attributed to a submaximal effort, it may also be 
present in more severe cases of CHF which can be associated with conditions such as a 
lower ratio of muscle mass to total blood volume (Sidney et al., 1977), reduction in active 
skeletal mass (Anainsson et al., 1981), or gradual diffusion of lactic acid metabolites 
from active skeletal muscle into circulation (Shephard et al., 1975). In the present study, 
many patients with a low V
.
O2peak seem to be unable to attain a RER typically 
representative of maximal effort (i.e., 1.10). However, a portion of this group may have 
been exercising maximally, but may not have been able to attain a RERpeak 1.10. Hence, 
an understanding of other variables that may predict CHF-related events within this group 
is critical. This will help in differentiating the patients at an increased risk of an event due 
to actual advanced disease from those who just have a low RERpeak due to a submaximal 
effort.  In this study, the dichotomous variables included to assess the event risk in the 
low RERpeak group were V
.
E/ V
.
CO2 slope, LVEF, CHF etiology, age, sex, BMI and beta-
blocker usage. A strength of this study is that all patients were first divided into low and 
high V
.
O2peak groups.  
 95 
Comparison of two-year CHF related event-free survival for CPX derived variables and 
beta-blockers in the low RERpeak group of each V
.
O2peak stratum:  
Higher V
.
E/ V
.
CO2 slope has been identified as an independent and strong 
predictor of poor prognosis in CHF patients (Corra et al., 2004). CHF patients show high 
V
.
E/ V
.
CO2 slope due to many central and peripheral factors such as reduced cardiac 
output, increased pulmonary artery and pulmonary capillary wedge pressure, increased 
ventilation-perfusion mismatching, and increased hypoxic chemoreceptor sensitivity. 
Because previous research has shown worse prognoses in patients with a V
.
E/ V
.
CO2 
slope >34 (Chua et al., 1997; Gitt et al., 2002; Guazzi et al., 2003; Arena et al., 2004), 
this cut-off was used in bivariate analysis in the present study. The high V
.
E/ V
.
CO2 slope 
(>34) group had a lower CHF-related event-free survival over two years (63.6%) than the 
low V
.
E/ V
.
CO2 slope group (83.2%) in the low RERpeak group (<1.10) of the low V
.
O2peak 
stratum (<14 ml/kg/min) (Fig. 5). This finding was also present in the low RERpeak group 
in the high V
.
O2peak stratum (Table 13) as the high V
.
E/ V
.
CO2 slope group had a lower 
event-free survival (71.1%) of patients than the low V
.
E/ V
.
CO2 slope group (95.6%).  
Poor survival with a higher V
.
E/ V
.
CO2 slope is consistent with findings of other 
researchers. Gitt et al. (2002) showed that CHF patients with a V
.
E/ V
.
CO2 slope >34 had 
a 5-fold increased risk of early mortality. In patients with a RERpeak 1.05, Corra et al., 
(2002) found patients with a higher V
.
E/ V
.
CO2 slope (>35) to have a significantly higher 
mortality rate than those with lower V
.
E/ V
.
CO2 slope (<35) (30% vs. 10% respectively). 
In patients with a RERpeak 1.10, Chua et al. (1997) demonstrated that patients with a low 
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V
.
E/ V
.
CO2 slope (<34) had significantly higher event-free survival (98%) than those with 
a higher slope (>34) (73%). The present study is unique in that a high V
.
E/ V
.
CO2 slope 
(>34) predicted CHF events in a group of patients with low RERpeak.   
LVEF is another important variable known to have an impact on prognosis in 
CHF patients. All patients included in this study had systolic heart failure with LVEF 
<40%. To assess the importance of LVEF in determining CHF prognosis, it was 
dichotomized as <25% or >25%. A LVEF <25% is typically considered to be severely 
depressed and is associated with higher mortality (Corra et al., 2002). Patients with a low 
LVEF had a lower CHF-related event-free survival (59.3%) over two-years than those 
with high LVEF (78.8%) within the group of low RERpeak in the low V
.
O2peak stratum 
(Fig. 6). The results were similar in the low RERpeak group of the high V
.
O2peak stratum 
(Table 13), where the event-free survival was lower (81.8%) in low the LVEF group than 
in the high LVEF group (93.8%). This finding is similar to earlier research done by Chua 
et al. (1997) and Mezzani et al. (2003) in patients with higher RERpeak. Chua et al. (1997) 
included CHF patients with RERpeak >1.10 and observed that non-survivors had a lower 
LVEF when compared to survivors. They also identified low LVEF as an independent 
predictor of event (death/transplant) in the multivariate analysis. However, the LVEF had 
not been dichotomized. The present study identifies the lower LVEF (<25%) patients to 
have increased risk of CHF related events even in patients with RERpeak <1.10 of low and 
high V
.
O2peak strata.  
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Etiology of CHF (ischemic versus non-ischemic) is another important prognostic 
variable in the CHF population. In the bivariate analysis for low RERpeak, low V
.
O2peak 
group, two-year event free survival was significantly lower (58.4%) in patients with 
ischemic etiology than those with non-ischemic etiology (76.6%) (Fig. 7). This finding is 
similar to that of both Myers et al. (1998) and Arena et al. (2005). The patients in the 
latter study had a mean RERpeak >1.0. Myers et al. (1998) observed that, in univariate 
analysis, the type of HF was a significant predictor of death whereas patients with 
ischemic etiology had significantly higher risk than those with non-ischemic etiology. 
Unlike the present study, the above mentioned studies did not observe the prognostic 
effect of etiology of CHF in low versus high RERpeak groups. The worse prognosis 
associated with ischemic etiology of CHF may be attributed to reduced functional 
capacity (De Feo et al., 2005), and alteration in left ventricular size and function as a 
result of ventricular remodeling following an ischemic insult.  
In recent years beta-blockers have been shown to improve the prognosis in CHF 
patients even without affecting V
.
O2peak (Pohwani et al., 2003). They have been shown to 
reduce the number of hospitalizations and improve the overall survival in CHF. In the 
low RERpeak group within the low V
.
O2peak stratum, the two-year event-free survival was 
lower in beta-blocker non-users (43.3%) as compared to beta-blocker users (74.7%) (Fig. 
8). Several other investigators have reported similar findings (Mezzani et al., 2003; 
Pohwani et al., 2003; Peterson et al., 2003). Pohwani et al. (2003) included patients of  
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V
.
O2peak <14 ml/kg/min with RERpeak >1.0 and followed them up for same CHF events as 
this study did. Conclusively, Pohwani et al. (2003) also suggested non-usage of  
beta-blockers as a criterion for heart transplantation candidacy. This observation is 
supported by Peterson et al. (2003) who demonstrated that beta-blocker non-users in a 
V
.
O2peak <14 ml/kg/min group had better survival with heart transplantation. The present 
study supports these results when RERpeak is <1.10 in the low V
.
O2peak stratum. The 
mechanism of improving survival in CHF by treatment with beta-blockers is not yet 
clear. It may be attributed to increased LV stroke volume, and decreased pulmonary 
artery pressure and pulmonary capillary wedge pressure (Metra et al., 2003).  
Additionally, blocking the sympathetic nervous system in CHF may contribute to further 
reduction of myocardial damage.  
It also has been suggested that heart transplantation will probably not add any 
additional survival benefits to CHF patients who are already receiving treatment with 
beta-blockers (Pohwani et al., 2003). However, these results did not hold true for the high 
V
.
O2peak group in the present study (Table 13). This is most likely due to the effect of high 
V
.
O2peak on improved survival in CHF. Peterson et al. (2003) also found that beta-blocker 
non-users in a patient group with V
.
O2peak >14 ml/kg/min had even better survival rates 
than patients who had undergone heart transplantation.  
No differences were found in the two-year risk for age (young vs. old), sex (males 
vs. females) , or BMI (low vs. high) in the low RERpeak groups in either V
.
O2peak strata 
(Fig. 9, 10, 11 and Table 13). Several other investigators have failed to demonstrate a 
 99 
relationship between age and risk of CHF events (Mancini et al., 1991,; Chua et al., 1997; 
and Davies et al., 2000). In addition, Davies et al. (2000) did not show sex to be related to 
CHF events.   
Comparison of significant risk variables in the low RERpeak, low V
.
O2peak group to the 
high RERpeak group:  
Two-year survival rates in the subgroups with variables shown to predict lower 
survival in the low RERpeak group were compared to survival rates in the high RERpeak 
group within each respective V
.
O2peak stratum. In the low RERpeak-low V
.
O2peak group, the 
survival of high V
.
E/ V
.
CO2 slope, beta-blocker non-use, low LVEF and ischemic etiology 
subgroups were compared against high RERpeak group. It was observed that event-free 
survival in the low RERpeak-non beta-blocker users was not only similar to, but even 
slightly lower than that of the high RERpeak group (Fig. 12). In addition, survival was just 
as poor in low RERpeak patients with high V
.
E/ V
.
CO2 slope (Fig. 13), low LVEF (Fig. 14), 
or ischemic etiology of CHF (Fig. 15) as was survival in the high RERpeak group within 
low V
.
O2peak stratum.  
For the high V
.
O2peak stratum, the patients in low RERpeak group with either a high 
V
.
E/ V
.
CO2 slope or a low LVEF were found to have significantly lower survival. When 
these two subgroups were compared against the high RERpeak group, they had even lower 
event-free survival than high RERpeak group (Table 14).  
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Overall, present study demonstrates that, the significant variables identified in the 
low RERpeak groups in both V
.
O2peak strata have similar or even higher risk of CHF related 
events as the high RERpeak group within a given V
.
O2peak stratum.  
Exploratory Analyses in Low V
.
O2peak Group:  
A multivariate proportional hazard analysis was performed to confirm the 
findings obtained on bivariate analyses and to identify independent predictors of CHF 
related events in patients with low RERpeak in the low V
.
O2peak stratum.  
The multivariate analysis was performed by including the variables V
.
E/ V
.
CO2 
slope (<34 or >34), LVEF (<25 or >25), beta-blocker treatment (users or non-users), 
etiology of CHF (ischemic or non-ischemic), age (<55 or >55), sex (males or females) 
and BMI (<30 or >30). The significant independent predictors of CHF related events 
were no beta-blocker treatment (p <0.001) and low LVEF (p <0.004) (Table 8). When 
beta-blocker usage was included in the model, V
.
E/ V
.
CO2 slope (p= 0.13) and HF 
etiology (p= 0.06) were no longer significant predictors of CHF related events.  
Beta-blocker usage confounded the analysis. Hence, V
.
E/ V
.
CO2 slope was then 
divided into four ventilatory classes (VC) described by Arena et al. (2007) as class I:  
V
.
E/ V
.
CO2 slope of <29, class II: V
.
E/ V
.
CO2 slope of 30-35.9, class III:  
V
.
E/ V
.
CO2 slope of 36-44.9 and class IV: V
.
E/ V
.
CO2 slope of >45 (Table 9). This 
ventilatory classification system has been established to help in better clinical decision-
making by assessing the severity of the disease more accurately than merely 
dichotomizing the variable at a value of 34. Kaplan-Meier analysis revealed that 
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increasing V
.
E/ V
.
CO2 slope was associated with a steadily lowering two-year event-free 
survival [VC I (92.3%), VC II (74.7%), VC III (67.8%) and VC IV (50.9%)] (Fig. 16).  
A multivariate proportional hazard analysis was conducted entering V
.
E/ V
.
CO2 
slope as the continuous variable as described above. In contrast to the earlier model, the 
V
.
E/ V
.
CO2 slope maintained statistical significance when beta-blocker use was included 
in the model. Additionally, the significance of the HF etiology variable increased from 
p=0.05 to p=0.02. Beta-blocker use (p <0.001), V
.
E/ V
.
CO2 slope (p= 0.01), LVEF (p= 
0.01), and etiology of CHF (p= 0.02) were shown to be significant independent predictors 
of CHF related events in patients with low RERpeak of low V
.
O2peak stratum (Table 10).  
When the effects of other clinical factors were considered, the V
.
E/ V
.
CO2 slope 
cut-point of 34 did not hold true as the significant independent predictor of CHF related 
events on multivariate analysis (Table 8). Among the four VC classes mentioned above 
(Fig. 16), patients with V
.
E/ V
.
CO2 slope >45 (VC IV) had the lowest two-year event-free 
survival (highest risk). Hence, the V
.
E/ V
.
CO2 slope was dichotomized as >45 and <45. 
The Kaplan-Meier analysis showed that high V
.
E/ V
.
CO2 slope group had significantly 
lower event-free survival (50.9%) than low V
.
E/ V
.
CO2 slope group (73.4%) (Fig. 17). 
Lastly, the multivariate analysis was conducted using V
.
E/ V
.
CO2 slope dichotomized at a 
value of 45.  The results showed that V
.
E/ V
.
CO2 slope maintained the significance even 
after entering beta-blocker use to the model. This multivariate analysis (Table 11) 
revealed that the following four variables appeared to be significant independent 
predictors of CHF related event: beta-blocker usage (p= 0.0001), V
.
E/ V
.
CO2 slope (p= 
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0.003), LVEF (p= 0.007), and etiology of CHF (p= 0.01). The statistical significance 
found with these variables was higher than with the earlier multivariate proportional 
hazard model. Age, sex, and BMI were not significant predictors of CHF related events. 
In summary, the following variables appear to be significant independent predictors of 
CHF related events in the low RERpeak group within the low V
.
O2peak stratum: no 
treatment with beta-blockers, V
.
E/ V
.
CO2 slope >45, LVEF <25%, and ischemic etiology 
of CHF.  
The strengths of this study are as follows: 1) The sample size (N=774) was large 
compared to other studies conducted in the past; 2) It included CHF patients with a wide 
range of functional capacity; 3) This study included LVAD implantation, heart 
transplantation, and deaths as the end points of follow-up, contrary to some other studies 
which used only mortality as an end-point; 4) This study assessed the risk of patients not 
attaining a RERpeak typically required to justify a test as ―valid‖; 5) Patients from multiple 
research sites were included, increasing the study‘s external validity.  
This study also has some limitations: 1) The follow-up period is limited to only 24 
months; 2) Duration of the medications that the patients are on is not controlled for; 3) 
This study included all-cause mortality instead of cardiac related mortality; 4) The 
follow-up information was dependent upon available hospital records; 5) Age at the onset 
of CHF, duration of illness, and previous physical activity levels were not considered.  
 In conclusion, this study is unique in that it analyzed the CHF patient 
population based upon RERpeak stratification after controlling for V
.
O2peak. Within the low 
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V
.
O2peak group, the high RERpeak group had lower survival than the low RERpeak group. 
However, certain factors (no use of beta-blockers, V
.
E/ V
.
CO2 slope >45, LVEF <25% 
and ischemic etiology of CHF) significantly predicted CHF events within the low 
RERpeak group.  These results suggest that advanced therapies, such as LVAD 
implantation and heart transplantation might still need to be considered for CHF patients 
who do not attain a RERpeak of 1.10 during CPX testing . Furthermore, although >34 is 
traditionally accepted as a prognostic value for V
.
E/ V
.
CO2 slope, the present study 
suggests that a slope of >45 may be a more independent predictor of CHF-related events 
in patients with low RERpeak and low V
.
O2peak. These results show promise for more 
appropriate treatment for certain CHF patients who may not ―perform well‖ during 
cardiopulmonary exercise testing.  Future studies using more sophisticated statistical 
modeling are needed to confirm these findings. Also, although the above mentioned 
variables have been identified as the significant independent predictors of CHF-related 
events in particularly low RERpeak -low V
.
O2peak group, it is important to study the 
interaction between these variables and to find any confounders if exist. Finally, it is also 
important to stratify RERpeak at lower cut-points, such as 1.05 and 1.0, to test if these 
variables in addition to others hold the same results as independent predictors of events. 
This will help clinicians in better decision making within the low RERpeak population.   
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